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ABSTRACT
HUMAN OLFACTORY EPITHELIAL-DERIVED PROGENITORS:
A POTENTIAL SOURCE FOR CELL THERAPY FOR PARKINSON'S DISEASE

MengWang
December 16th, 2011
Human adult olfactory epithelium contains neural progenitors (hONPs) which replace
damaged cellular components throughout life. Methods to isolate and expand the hONPs
have been developed in our laboratory. In response to morphogens, the hONPs
differentiate along several neural lineages. This study optimized conditions for the
differentiation of hONPs towards dopaminergic neurons. The hONPs were treated with
Sonic Hedgehog, in the presence or absence of Retinoic acid and/or forskolin.
Transcription factors (Nurrl, Pitx3 and Lmxla) that promote embryonic mouse or
chicken dopaminergic development were employed to determine if they would modulate
lineage restriction of these adult human progenitors. Transcription factor expression and
tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, were detected in
the transfected cells after 4-month selection with G418, indicating transfected hONPs
were stably restricted towards a dopaminergic lineage.

Furthermore, enzyme

immunoassay was employed to detect the synthesis and release of dopamine. The most
efficient dopamine transfection paradigm was determined. Equivalent levels of several
neurotrophic factors were detected in both the pre- and post-transfected hONPs which

v

have potential roles in the maintenance, survival and proliferation of dopaminergic
neurons.

This study engrafted cells modified by the most efficient transfection paradigm for
dopamine formation into a unilateral neurotoxin, 6-hydroxydopamine (6-0HDA)-induced
Parkinsonian rat model. Thirty-five percent of the animals engrafted with hONPs had
improved behavioral recovery as demonstrated by the amphetamine induced rotation test
as well as a comer preference and cylinder paw preference, over a period of more than 24
weeks. No difference was observed between the pre- and post-transfected groups
indicating that the host environment facilitated dopaminergic differentiation in situ.
Human fibroblasts did not diminish the Parkinsonian rotational deficits at any point
during the study. The engrafted hONP population remained intact and TH positive for a
minimum of six months in vivo. Higher dopamine leveis were detected in the striatum of
behaviorally recovered animals than in equivalent regions of their non-recovered
counterparts. Throughout these experiments, no evidence of tumorigenicity was
observed. These studies support our hypothesis that human adult olfactory epithelialderived progenitors represent a unique autologous cell type for a cell-based strategy for
the treatment of Parkinson's disease.
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CHAPTER I

GENERAL INTRODUCTION
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Parkinson's disease (PD) remains one of the leading causes of chronic degenerative
neurological disability, which affects more than 6,000,000 people world-wide, with
approximately 60,000 new cases diagnosed each year in the United States
(NationalParkinsonFounfdation,

2010).

The

incidence

nses

with

age,

being

approximately 1: 1000 overall and 1% of the population over the age of 60 and 4% in
those over 80 years. Unfortunately, the mortality rate of PD has increased steadily in
recent years (de Lau and Breteler, 2006; Anderson and Caldwell, 2007) as the population
longevity has increased (Savica et aI., 2010). One of the early stage symptoms is the loss
of smell (Zucco et aI., 1991; Zucco et aI., 2001) and the later symptoms are movementrelated, including shaking, rigidity, slowness of movement and difficulty with walking
and gait (Inoue et aI., 2007; Garcia-Ruiz, 2011). At more advanced stages of the disease,
problems with dementia may commonly arise (Klassen et aI., 2011; Parekh, 2011). The
cause of PD remains unknown and it is characterized by the extensive loss of
dopaminergic (DA) neurons in the substantia nigra (SN) in the midbrain (Homykiewicz,
1973b).
Dopamine is a neurotransmitter that can function as a hormone which mainly inhibits
the release of prolactin from the anterior lobe of the pituitary (Benes, 2001). Dopamine is
synthesized in body first by the hydroxylation of the amino acid L-tyrosine to L-DOPA
via the enzyme tyrosine hydroxylase (TH), which has been widely used as a marker for
dopaminergic neurons (Sauer et aI., 1993; Takeuchi et aI., 2005; Redmond et aI., 2007).
L-dopa is then decarboxylized by aromatic L-amino acid decarboxylase to the final
product, dopamine (Figure 1) (Barger and Dale, 1910). Dopaminergic neurons are
primarily found in the substantia nigra (SN) and the ventral tegmental area (Wise, 2004)
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and they have many important roles in the brain, including voluntary movements,
behavior and motivation (Vadasz et ai., 1992b, 1992a; Stoessl, 1996; Da Cunha et ai.,
2009).
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Figure 1. Chemical formula and biosynthesis for dopamine.
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Currently the principle treatment for PD is oral L-3,4-dihydroxyphenylalanine (Ldopa) (Bidet-Ildei et aI., 2011), which is the precursor of dopamine that can pass the
blood-brain-barrier (Hornykiewicz, 1973a). L-dopa promotes symptomatic relief. Patients
who took L-dopa improved in their motor function, activities of daily living and quality
of life of the patients (Evans et aI., 1980; Kalinderi et aI., 2011). However, with time the
drug becomes less effective for two reasons: 1. During the progression of the disease the
neurons become less sensitive to the drug (Callaway, 2011) and 2. L-dopa does not
prevent or rescue the DA neurons from degeneration (Lang and Lozano, 1998; Sheng et
aI., 2010). Furthermore, dyskinesia was eventually developed after several years of
treatment with L-dopa (Friedman, 1985; Wedekind, 2005). Dyskinesia is characterized
by twisting, jerking or dance-like movement, mostly of the arms and/or face. This
symptom results from changes in striatal signaling after long-term pulsatile dopaminergic
stimulation (Stacy and Galbreath, 2008). Clearly, an alternative treatment that can
provide long-term recovery with no side-effects is needed.
A. Cell Replacement Therapy

The basic concept of cell replacement therapy is to restore function lost as a result of
the disease in the central nerVous system (CNS) by replacing degenerating or lost cells
with viable functional cells. Recent research has attempted to find cell populations that
can be used to replace lost or degenerating dopaminergic neurons (Anderson and
Caldwell, 2007; Parish et aI., 2008). Studies have employed neural cell grafts obtained
from the fetal ventral mesencephalic (VM) dopaminergic neurons, and were able to
successfully relieve the Parkinsonian symptoms following the embryonic tissue
transplantation (Lindvall et aI., 1988; Madrazo et aI., 1988; Lindvall et aI., 1992;
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Freeman et aI., 1995; Borlongan, 2000; Ganser et aI., 2010). However, this treatment
frequently resulted in significant dyskinesia (Freed et aI., 2001; Olanow et aI., 2003;
Barker and Kuan, 2010; Lane et aI., 2010). Even when positive clinical improvements
were achieved in the absence of dyskinesia, the amount of tissue required for each PD
patient necessitated a minimum of 4-5 fetal brains (Mendez et aI., 2005). This
requirement increased the possibility of viral or bacterial infection and the lack of donor
source has significantly limited the utility of this approach. In addition the number of
surviving neurons was highly limited as the majority of the engrafted cells died in the
initial days following transplantation (Borlongan, 2000; Barker and Kuan, 2010; Ganser
et aI., 2010). The limited supply of fetal VM cells coupled with their poor graft viability
severely limited the therapeutic utility of this population for the treatment of PD.
Therefore, an alternate expandable source of dopamine cells has become a major research
focus (Daadi, 2002; Doss et aI., 2004; Lindvall et aI., 2004; Xiong et aI., 2011).
B. Stem Cells

Stem cells are undifferentiated cells with an unlimited capacity for self-renewal and
the potential for lineage restriction (maturation) into one or more specific cell types,
depending on their origin and the micro-environmental signals that they receive (Lindvall
et aI., 2004; Hwang et aI., 2010). These characteristics make stem cells an attractive
target population for PD cell replacement therapy (Snyder and Olanow, 2005; Sonntag et
aI., 2005; Kim, 2011; Tonnesen et aI., 2011). Recent studies also suggest that the
engraftment of stem cells or progenitors can up-regulate or enhance existing endogenous
progenitor populations (Redmond et aI., 2007; Abdel-Salam, 2011; Ruff et aI., 2011).
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Stem cells can be divided into three major groups: embryonic stem cells, induced
pluripotent somatic cells and adult human stem cells. Embryonic stem cells (ESC)
originate from the inner cell mass of blastocysts (Thomson et aI., 1998). Mouse and
porcine ESCs have been employed in cell replacement strategies for the treatment of PD
animal models and behavioral improvements have been observed (Lonardo et aI., 2010;
Yang et aI., 2010). However, a source of human cells is essential for clinical trials.
Human embryonic stem cells were first isolated in 1998 from totipotent cells of the early
mammalian embryo (Thomson et aI., 1998). This was a breakthrough in the stem cell
research field for these cells maintained their capacity for stable developmental
restriction to form derivatives of all three embryonic germ layers even after prolonged
culture (Thomson and Marshall, 1998). Dopaminergic lineage restricted ESCs were
transplanted into different kinds of PD models, such as the 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) lesioned non-human primate model (Bjugstad et aI., 2008), or
the 6-hydroxydopamine lesioned rodent model (Park et aI., 2003; Brederlau et aI., 2006;
Geeta et aI., 2008). Parkinsonian deficits were greatly relieved in the models that received
ESC engraftment. However, unfortunately 50% of these animals were found to develop
tumors within 6-8 weeks after cell transplantation (Arnhold et aI., 2004; Hedlund et aI.,
2007). Furthermore, ethical concerns in using human embryos have limited the use of this
cell source in clinical studies.
Human induced pluripotent stem cells (iPSC) may also represent a promIsmg
resource according to recent studies (Hargus et aI., 2010; Chang et aI., 2011; Soldner et
aI., 2011). They can be isolated from a variety of tissues, such as human fibroblasts
(Takahashi and Yamanaka, 2006; Takahashi et aI., 2007), human or rat primordial germ
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cells (Shamblott et aI., 1998; Okita et aI., 2007; Hamanaka et aI., 2011), or mammalian
embryos (Martin, 1981; Nichols et aI., 1998). These cells can be reprogrammed to an
"embryonic-like" state by transfer of nuclear contents into oocytes or by fusion with ES
cells after being obtained from adult human somatic cells (Takahashi and Yamanaka,
2006). Human iPSCs are similar to hESCs in morphology, proliferation, surface antigens,
gene expression, epigenetic status of pluripotent cell-specific genes, and telomerase
activity (Takahashi et aI., 2007). Therefore, human embryonic stem cells (hESCs)
(Brederlau et aI., 2006) and human induced pluripotent stem cells (iPSC) are both
promising resources according to recent studies, with behavioral improvement in animal
models of PD (Hargus et aI., 2010; Chang et aI., 2011; Soldner et aI., 2011). However,
like the ESC transplantation studies, in many cases animals received iPSCs, tumors
containing a variety of tissues from all three germ layers formed within 9 weeks
following the stem cell engraftment (Takahashi and Yamanaka, 2006; Chang et aI.,
2011). This result severely limits the utility of these two cell sources.
Collectively the studies illustrated above provide "proof of concept" that cell
replacement therapy is a viable and hopeful therapeutic strategy for the treatment of
individuals with PD. What is needed is a cell source to replace lost or damaged DA
neurons which is stable, will not be tumorigenic, avoids the need for immunosuppressive
agents, and eliminates the search for available donors as well as the ethical concerns
associated with embryonic tissues.

C. Human Adult Olfactory Epithelial Derived Neural Progenitors
The olfactory epithelium is the only tissue in adult human that contains neural
progenitors, which undergo neurogenesis throughout life without trauma (Sosnowski et

7

aI., 1995; Calof et aI., 1998; Zhang et aI., 2000). Therefore, it is considered a unique
source for the development of adult human stem cells. Human olfactory epitheliumderived progenitors (hONP) have been identified and successfully isolated in our
laboratory (Roisen et aI., 2001). To date more than 150 patient-specific cell lines of
human olfactory neural progenitors (hONPs) have been established from primary cultures
of human adult olfactory epithelium isolated from cadavers (Roisen et aI., 2001) and
patients undergoing endoscopic sinus surgery (Winstead et aI., 2005). This tissue is a
unique source for neural progenitors that can be harvested by minimally invasive
endoscopic nasal surgery without a craniotomy (Winstead et aI., 2005). This population
is an autologous cell source which provides total histocompatability and thus eliminates
the need for immunosuppressive therapy as well as the ethical concerns and long waiting
lists for available matched tissue.
Previously our laboratory has shown that the hONPs have the potential to
differentiate along several neural lineages following exposure to environmental signals in
vitro (Marshall et aI., 2005; Zhang et aI., 2006). Therefore, the present study was

designed to determine: 1. If hONPs could be lineage restricted towards dopaminergic
neurons with a proper local microenvironment; 2. To optimize the methodology for
hONPs differentiation to dopaminergic neurons; 3. To determine if hONPs will function
in a unilateral 6-hydroxydopamine (6-0HDA) lesioned rat model of Parkinson's disease
(Wright et aI., 2009).
In this dissertation, the second chapter will describe how the hONPs can be lineage
restricted to dopaminergic neurons, with the method of genetic manipulation and
morphogenic treatment. It will also be shown that the transfection did not alter the
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capability of the hONPs to produce neurotrophic factors, which are essential in the
development of dopaminergic neurons. The most efficient transfection paradigm will be
discussed and further transplanted into an animal model of PD. Chapter III will address
the pilot studies for the following in vivo studies: the ideal animal model and the proper
engrafting cell number/concentration and site. In chapter IV, the in vivo studies utilizing
transfected and non-transfected hONPs implanted into the striatum, as well as a
population of human fibroblasts and the medium as controls will be described. The
observed behavioral recovery following engraftment of transfected and non-transfected
hONP will be presented. Since equivalent results were obtained with both the pre- and
post-transfected hONPs, these studies suggest that the hONPs without genetic
manipulation have a high potential in the treatment of PD models. It was also
demonstrated that the dopamine levels in animal brains were related to their behavioral
improvement. In the final chapters, evidence will be presented which support our
hypothesis that hONPs may represent an ideal autologous population for cell therapy for
Parkinson's disease. The future studies are discussed which aim to identify mechanism of
hONPs action on behavioral improvement in the PD models and to increase the recovery
rate.
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CHAPTER II
LINEAGE RESTRICTION OF ADULT HUMAN OLFACTORY
EPITHELIAL DERIVED PROGENITORS TO DOPAMINERGIC
NEURONS

Meng Wang, Chenliang Lu, Hong Li, Mengsheng Qiu, Welby, Winstead
and Fred J. Roisen

Published in Stem Cell Discovery, 2011, VoU No.3 PP.29-43.
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A. Introduction

As it has been introduced in Chapter I, this study is aiming to find an ideal source for
cell-mediated treatment for Parkinson's disease due to theirunlimited capacity for selfrenewal and the potential for lineage restriction (maturation) into one or more specific
cell types, depending on their origin and the micro-environmental signals that they
receive (Lindvall et aI., 2004; Hwang et aI., 2010). Stem cells are considered an attractive
target population for PD cell replacement therapy (Snyder and Olanow, 2005; Sonntag et
aI., 2005; Kim, 2011; Tonnesen et aI., 2011). Human embryonic stem cells (hESCs),
lineage-restricted towards dopaminergic neurons when transplanted into a rodent model
ofPD, provide a significant relief of symptoms (Schulz et aI., 2004). However, with time,
animals engrafted with hESCs have frequently developed teratomas (Brederlau et aI.,
2006). Human induced pluripotent stem cells (iPSC) are promising resource according to
recent studies (Hargus et aI., 2010; Chang et aI., 2011; Soldner et aI., 2011). These cells
can be obtained from adult human somatic cells and reprogrammed to an "embryoniclike" state by transfer of nuclear contents into oocytes or by fusion with ES cells
(Takahashi and Yamanaka, 2006). Human iPSCs are similar to hESCs in morphology,
proliferation, surface antigens, gene expression, epigenetic status of pluripotent cellspecific genes, and telomerase activity (Takahashi et aI., 2007). Transplantation of iPSCs
has been shown to diminish some of the Parkinsonian behavioral deficits in several
rodent models ofPD; unfortunately in many cases similar to their embryonic counterparts
the engrafted population formed, tumors containing a variety of tissues from all three
germ layers (Takahashi and Yamanaka, 2006; Chang et aI., 2011).

Collectively the

studies illustrated above provide "proof of concept" that cell replacement therapy is a
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viable and hopeful therapeutic strategy for the treatment of individuals with PD. What is
needed is a cell source to replace lost or damaged DA neurons which is stable, will not be
tumorigenic, avoids the need for immunosuppressive agents, and eliminates the search
for available donors as well as the ethical concerns associated with embryonic tissues.
The olfactory epithelium (OE) is a unique source for neural progenitors (multipotent
neural stem cells) that can be harvested by minimally invasive endoscopic nasal surgery
without a craniotomy (Winstead et aI., 2005a). Furthermore, since no demonstrable
olfactory deficits result from OE biopsy, the tissue can be used to generate an autologous
progenitor population from patients with PD (Winstead et aI., 2005a). An autologous cell
source

provides

total

histocompatability

and

thus

eliminates

the

need

for

immunosuppressive therapy as well as long waiting lists for available matched tissue.
Previously our laboratory developed methods for the isolation and culture of a
neurosphere forming population of neural progenitors (Roisen et aI., 2001a). To date
more than 150-patient-specific cell lines of human olfactory neural progenitors (hONPs)
have been established from primary cultures of human adult olfactory epithelium isolated
from cadavers (Roisen et aI., 2001a) and patients undergoing endoscopic sinus surgery
(Winstead et aI., 2005a). Our studies have shown that the hONPs have the potential to
differentiate along several neural lineages following exposure to environmental signals in
vitro (Marshall et aI., 2005; Zhang et aI., 2006a). Therefore, with a proper local

microenvironment, the hONPs have the potential to mature to dopaminergic neurons
(Zhang et aI., 2006a).
Molecular techniques were applied for the transfection of Nurrl (Perlmann and
Wallen-Mackenzie, 2004b; Kim, 2011), Pitx3 (Maxwell et aI., 2005; Courtois et aI.,
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2010) and Lmx1a, transcription factors which promote dopaminergic differentiation. It
has been reported that gene pitx3 and nurr1 are essential for the survival and
differentiation of DA neurons in the striatum (Perlmann and Wallen-Mackenzie, 2004a;
Maxwell et aI., 2005; Haubenberger et aI., 2011). Both transcription factors function as
dopaminergic promoters in chick, mouse, or human embryonic cells (Saucedo-Cardenas
et aI., 1997; Hwang et aI., 2003a; Courtois et aI., 2010; Katunar et aI., 2010), and we first
demonstrated that they participate in dopamine production in adult human olfactoryderived progenitors (Soldner et aI., 2011). Furthermore, the genes pitx3 and nurr1 were
found to induce TH expression synergistically (Martinat et aI., 2006; Soldner et aI.,
2011). In these studies the hONPs were genetically modified by transfecting gene pitx3
and nurr1, after which they were tyrosine hydroxylase (TH) positive even after four
months of selection. The transfection effects of different paradigms were evaluated and
compared.
Several studies have shown that neurotrophic factors, such as brain-derived
neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), neurotrophin-3 (NT-3),
etc. are important for the survival and function of dopaminergic neurons in CNS
(Karamohamed et aI., 2005; Singh et aI., 2006; Li and Ding, 2010; Edalat et aI., 2011;
Pessach and Notarangelo, 2011). Recent studies also indicate that the neurotrophins have
the potential to optimize the local micro-environment of the damaged area, and thereby
induce endogenous stem cells to replace or rescue degenerating neurons (Lindvall and
Kokaia, 2010; Kassis et aI., 2011). HONPs derived from adult human olfactory
epithelium have been shown to produce and release neurotrophins (Zhang et aI., 2000;
Zhang et aI., 2003; Marshall et aI., 2006), which could further support their use in a cell-
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based therapy for PD. Therefore, this study also evaluated the ability of pre and post
transfected hONPs to synthesize key neurotrophins.
The 1st objective of this study was to determine if hONPs could be lineage restricted
towards dopaminergic neurons and if so to optimize the methodology, followed by
determining and evaluating the function of IPN transfected and pre-transfected hONPs in
a unilateral 6-hydroxydopamine (6-0HDA) lesioned rat model of Parkinson's disease
(Wright et aI., 2009).
B. Material and Methods
1.

Cell culture

The two patient-specific olfactory progenitor lines used in this study were obtained from
adult olfactory epithelium harvested from a 42-year-old female patient and a 20-year-old
male via endoscopic biopsy (Roisen et aI., 2001 b). The tissues were cultured to allow the
emergence and harvest of hONPs as previously described (Zhang et aI., 2004; Winstead
et aI., 2005b). The hONPs were thawed from frozen stock that was maintained in liquid
nitrogen and cultured in minimal essential medium (MEM) with 10% heat inactivated
fetal bovine serum (FBS, GIBCO, Grand Island, NY) (lO%OE) for one week. The
hONPs were adapted to serum-free growth media via serial dilution of serum every day
for 4 days until the cells were finally cultured in DFBNM (DMEM/FI2 supplemented
with 1% B27 and 0.5% N2 and 100

~g/ml

gentamycin (GIBCO, Grand Island, NY)

(Zhang et aI., 2004). Parallel independent experiments were performed on hONP lines
from the two different patient lines. Since equivalent results were achieved, data from
only one line has been presented.
2. Construction of expression plasmids (Figure 2)
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The mouse nurri eDNA was cloned into the pLNCX2 expression vector (Clontech)
between CIal. Similarly, the rat pitx3 and mouse lrnxia eDNA were inserted into
pLNCX2 vector between Clal. For the nurri and pitx3 co-expression vector, nurri eDNA
was cloned into pIRES (CIon tech ) between Xbal and Sail, and pitx3 was inserted
between EcoRI. The pLNCX2 and pIRES expression vectors served as controls. All
expression vectors were verified by extensive DNA sequencing.

EcoRl

EeoR l

Nurrl+Mye

Pitx3+Mye

PLNCX2-pitx3

PLNCX2-nurrl

EeoRl

Nurrl+Mye
Lmxla+Myc

PLNCX2-lmxla

PIRES-pitx3-nurrl

Figure 2. Construction of Expression Plasmid
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Sail

All plasmid constructs were introduced into the hONPs by liposomal transfection.
4

The cells were plated on glass coverslips in six-well plates (5 x 10 cells per 35-mm well)
in DFBNM without antibiotics 1 day before transfection. HONPs were transfected with
each plasmid (4/-lg/well) for 24 hours according to the manufacture's protocol
(Lipofectamine 2000, Invitrogen, Carlsbad, California). One day after transfection, the
cells were fed with 10% FBS in MEM and selected with G418 (400/-lg/ml; Invitrogen,
Carlsbad, California). The selection pressure was kept for up to 4 months to insure a
purified stably transfected cell population. Immunocytochemistry and Western blot
analysis were applied to detect several dopaminergic neuronal markers. After a fourmonth selection, the transfected hONPs were frozen in liquid nitrogen for additional foursix months of storage. After removal from cryostorage and several days' recovery in
MEM with 10% FBS at 37°C, the dopaminergic lineage restriction was probed with
immunocytochemistry and Western blot analysis.
4. Treatment with Morphogens
The hONPs were treated with Shh, in the presence or absence of RA (1/-lM) and/or
FN (5/-lM) (Zhang et aI., 2004). Highly purified Shh (kindly provided under a Material
Transfer Agreement with Curis and Wyeth, Inc.) was applied to hONPs and compared to
a commercially available control sample obtained from Sigma to determine the extent to
which purification of Shh can affect the expression of tyrosine hydroxylase (TH). The
hONPs were plated on glass coverslips in six-well plates (5

x

104 cells/35mm well) in

DFBNM and treated with medium containing various concentrations and combinations of
RA, FN, and Shh for 7 days (C02 atmosphere at 5% and temperature of 37°C). Treatment
with Shh included several concentrations; 0.25mg/ml (Shh0.25), O.lmg/ml (ShhO.l),
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0.05mglml (ShhO.05), 0.025mg/ml (ShhO.025) in the presence or absence of retinoic acid
1 J,lM RA (RAI) and/or forskolin, 5 J,lMFN (FN5). After treatment, the TH expression
was determined at 1-7 days in vitro by immunocytochemical analysis. Once the
optimized environment for inducing dopaminergic neurons was determined, the medium
containing the optimized combination was applied to stably transfected hONPs to further
improve the yield of these neurons.
5. Immunocytochemistry
The hONPs (5

x

104 cells/well) were plated on 35 mm round glass covers lips in six-

well plates (Becton, Dickinson and Co.) and incubated at 37 DC in 5% CO z/95% air for
24 hours and treated with RA, FN, and Shh or transfected and selected for different
periods of time prior to fixation for immunofluorescence. 4, 6-diamidino-2-phenylindole
dihydrochloride (DAPI) (1: 1,000, 2 mg/ml, Molecular Probes, Eugene, OR) was applied
in culture for 30 minutes at 37 DC for vital nuclear staining. The coverslips were rinsed
with cytoskeletal buffer (CB) twice and fixed in 3% paraformaldehyde in CB (10
minutes). 0.2% Triton X-IOO (10 minutes, Sigma) in tris buffered saline (TBS) was
applied and cells were incubated (1 hour) in 3% bovine serum albumin (BSA) in TBS.
Primary antibodies were applied overnight (4 DC). After 30 minutes washing (10 minutes
each, 3 times) in TBS, the cells were incubated with secondary antibodies: Texas-red
conjugated goat anti-rabbit immunoglobulin G (IgG) , Texas-red-conjugated goat antimouse IgG, Cy2-conjugated goat anti-mouse IgG and/or Cy2-conjugated goat anti-rabbit
IgG (all diluted 1:600, Cy2, Jackson Immunology Research Laboratories; Texas red,
Molecular Probes). The coverslips were rinsed in TBS for 30 minutes (10 minutes each, 3
times) and mounted on slides. The slides were examined with confocal microscopy. All
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experiments were repeated a minimum of two times to ensure the specificity of staining;
only one set of data has been presented since similar results were obtained.
6. Western Blot Analysis
Western

blot

analysis

was

used

to

further

examme

and

confirm

the

immunofluorescence studies. Proteins from hONPs transfected with control vectors, as
well as hONPs transfected with the vectors plus each combination of transcriptions
factors (pLNCX2-pitx3, pLNCX2-nurrI, pLNCX2-lmxIa, pIRES-pitx3-nurrl), cultured
in DFBNM, selected in all groups were collected in cell lysis buffer (Sigma, St. Louis,
MO). After 15 minutes of incubation on ice, samples were centrifuged for 30 minutes
(4°C) and the protein concentration of each supernatant was determined. The protein
samples (20Ilg/well) were electrophoresed on 10% SDS-polyacrylamide gels along with
standardized-molecular-size marker proteins in an adjacent lane and transferred from gel
to nitrocellulose paper. Nonspecific binding was blocked (1 hour) with 5% nonfat dry
milk in TBS-Tween (TBST) buffer. Blots were incubated (4°C overnight) in primary
antibodies (anti-TH, MAB; anti-actin, MAB). Blots were washed three times for 10
minutes in TBST, after which they were incubated (1 hour, room temperature)
monoclonal horseradish peroxidase-labeled anti-mouse IgG (1:2,000). ECL Western
blotting detection reagents (Amersham Biosciences) were used to identify bound
antibodies. Densitometry of the protein bands was carried out on a high performance
chemiluminescence film (Amersham Biosciences). Data was analyzed using the Image-J
software programs supplied by the NIH official website (http://rsb.info.nih.gov/iil).

7. Dopamine assay
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Stably transfected hONPs were plated into flasks (25cm

2

,

Corning) at 10 5 per flask

before they were adapted to the absence of serum via serial dilution of serum every day
for 4 days until the cells were finally cultured in DFBNM, which was collected daily after
the serum was totally eliminated from the medium. The DFBNM collected from each
restricted NSFC line was then concentrated to 1150 volume respectively by centrifugal
filters (Amicon Ultra-I5, Millipore). The differentiated hONPs were then collected and
lysed (lysis buffer, Sigma). Dopamine expression was analyzed quantitatively in the
concentrated medium as well as in the celllysates with a dopamine enzyme immunoassay
kit (Dopamine EIA, Immuno Biological Laboratories, Inc.), according to the
manufacture's protocol.

8. Neurotrophin Assay
Pre- and post-transfected hONPs were plated into flasks (25cm2 , Corning) at 5xI0 5
per flask and cultured in 10% OE media for two days before they were adapted to the
absence of serum via serial dilution of serum every day until they were finally cultured in
DFBNM. The differentiated hONPs were then collected and lysed (lysis buffer, Sigma).
Neurotrophins were detected in the extracted protein with different enzyme-linked
immunosorbent assay (ELISA) kits (BDNF, Chemicon; CNTF, Quantikine; NT-3,
Chemicon) respectively, according to the manufacture's protocol. The ELISA absorbance
(OD) was obtained with a microplate spectrophotometer (Spectramax Plus), and the
results were plotted and calculated with the compatible software (Softmax Pro).
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C. Results
Cryopreserved vials of the two representative hONP lines were obtained from storage
and grown for 1-2 weeks prior to the start of these experiments to insure equivalent
passage (4-8) and sufficient cell numbers for the following studies.
1. Transfection of Olfactory-derived progenitors (hONPs) to achieve dopaminergic
lineage restriction.
1.1 HONPs were obtained from previously frozen stock with low passage number (48) and maintained in MEMlO medium during their recovery period. These mitotically
active cells divided every 18 - 20 hour which typically required passage three times per
week as previously described. The heterogeneous nature of the hONP population prior to
transfection was determined by immunocytochemistry. No reactivity was observed for
pitx3, nurrl, lmxla with pre-transfected hONPs and only a few (5-10%) of them were
positive for the dopamine precursor, TH, when treated conditionally (Zhang et aI.,
2006b). Low passages (Passage 4-8) of hONPs from 2 different patient-specific cell lines
were employed in parallel transfection experiments. To examine the phenotypic
expression of hONPs after transfection and selection, representative cultures as well as
their respective pre-transfection controls were evaluated. Non-transfected hONPs or those
transfected with lipofectamine alone died within 1 week after selection with 400j.lg/ml
G418. In contrast, 30% of the transfected cells (both with the concerned genes and the
control vectors) survived under the selection pressure. Transfection with control vectors,
single genes, or pitx3-nurrl combined resulted in no morphologic changes compared to
the typical pretreated hONPs. However, the transfected hONPs divided more slowly, with
a new doubling time of three to four days, which required a feeding schedule of only
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twice a week and necessitated passage every 9-10 days. Immunofluorescent analysis of
the transfected populations demonstrated that hONPs were stably transfected and TH
expressed.
1.2 Human olfactory derived hONPs were transfected by pIRES-pitx3-nurrl to
restrict them towards DA neurons. The vector alone was employed as a control. To obtain
a purified population of restricted cells the transfected population was maintained in
G418 for selection. Although only several weeks of selection produced relatively pure
populations, an interval of four months was employed to insure stability and purity.
HONPs remained TH positive after transfection of pIRES-pitx3-Nurl, whereas the
transfection of control vectors exhibited no phenotypic changes, demonstrating that
hONPs can be restricted towards dopaminergic neurons. (Figure3)
1.3. HONPs were transfected with pLNCX2-nurrl, pLNCX2-pitx3, pLNCX2-lmxla
or the vector alone as a control. The transfected cells were exposed to G418 for selection
for periods up to 4 months. HONPs were TH positive after transfection ofpLNCX2-nurrl
and pLNCX2-pitx3, whereas the transfection of control vectors resulted in no phenotypic
changes. Therefore pLNCX2-nurrl or pLNCX2-pitx3 can be employed to lineage restrict
the hONPs towards dopaminergic neurons. In contrast, the hONPs transfected with
pLNCX2-lmxla remained unreactive for TH, although positive of myc, which
demonstrated the successful incorporation of the plasmid. (Figure 3)
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Figure 3. Immunocytochemical analysis. HONPs transfected with pIRES-Pitx3- Nurrl,
pLNCX2- Pitx3 or pLNCX2-Nurrl were tyrosine hydroxylase (TH) positive after 4
months selection with G418 (c, d, f, g), while the lines transfected with pIRES or
pLNCX2 were TH negative (b, e). HONPs transfected with pLNCX2-Lmxla were Myc
positive, demonstrating that the plasmid was transfected into the nucleus (h).
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1.4. Western Blot analysis was employed to confirm quantitatively the
immunocytochemical studies of the transfected NSFC populations. The following
transfected lines were analyzed for TH expression:

hONPs transfected with pIRES-

pitx3-nurrl, pLNCX2-nurrl, pLNCX2-pitx3 and pLNCX2-lmxla all of which were TH
positive, which indicated their potential to release dopamine. In contrast, the hONP
populations' transfected with the control vectors (pIRES and pLNCX2) did not exhibit
TH expression.

~-actin,

a protein that is widely expressed in all mammalian and avian

cells was used as a reference protein for the comparison of TH expression by the various
lines. Image-J was applied for the data analysis. Each curve from B to M in Figure 2
illustrates the density of bands evident on the western gel (Figure4 A), and the area that
each curve circles was measured. The bars in picture N represent the ratio of TH
expression and ACTIN expression in the cell line. HONPs transfected with pIRES-pitx3nurrl exhibited the highest ratio for the TH and ACTIN expression, while the cells
transfected with the control vector (pLNCX2 or pIRES) had the least TH staining (Figure
4 B-N). These results demonstrate that individual transcription factors have unique
abilities in promoting the dopaminergic restriction ofhONPs.
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Figure 4 A. Western blot analysis. B-G. Scanning densitometry demonstrates ACTIN-

expression in a hONP line of pLNCX2, pLNCX2-pitx3, pLNCX2-nurrl, pIRES and
pIRES-pitx3-nurrl respectively. H-M. Densitometry of TH-expression as shown in A. N.
Histogram demonstrating the ratio ofTHI Actin produced by each population.
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2.

Transfected hONPs remain restricted to dopaminergic lineage after removal

from cryostorage.

After 4 month-selection, the dopaminergic lineage restricted cells were cryopreserved
in liquid nitrogen for additional 4-6 months. Following their removal from cryostorage
and several days' recovery in MEMIO at 37°C, all but one of the transfected hONP
populations survived under the selection pressure of 400~glml G418, demonstrating that
these cells were stably transfected and retained their potential for long term storage and
clinical application. Immunocytochemistry and Western blot analysis was applied to
these previously stored populations to examine their TH expression. The hONPs
transfected with pLNCX2-pitx3, pLNCX2-nurrl and pIRES-pitx3-nurrl remained
healthy and TH positive under the pressure of selection, while the pLNCX2-lmxla
transfected line did not (Figure 5).
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Figure 5. Immunocytochemistry (A-G) and western blot analysis (I) demonstrating that

hONPs transfected with pLNCX2-pitx3, pLNCX2-nurrl and pIRES-pitx3-nurrl remain
healthy and TH positive following removal from cryostorage under selection pressure (D,
F, G). In contrast, the Lncx2-lmxla transfected line no longer expressed TH (H).
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3. Lineage restricted hONPs produced and released dopamine.

After removal from the cryostorage, dopamine production was detected in the hONP
lines which were stably transfected with concerned genes, while the cells transfected with
control vectors and the non-transfected hONPs didn't produce dopamine. The dopamine
level of each sample was then divided by the concentration of protein in each specific
hONP line to calculate the efficiency of dopamine production. Among all the 4 gene
transfected lines, hONPs transfected with pIRES-pitx3-nurrl exhibited the most efficient
dopamine formation (Figure 6). Spent medium was collected 4 days after culturing the
lineage restricted hONPs. This medium was then concentrated to 1/50 volume respectively,
and dopamine E.I.A. was applied to detect the dopamine release (extracellular levels). Data
was calculated in the same manner as the intracellular dopamine analysis. Lower levels of
dopamine were detected in the concentrated media compared to the corresponding analysis
of the cell lysis. The greatest level of dopamine release was detected in pIRES-pitx3-nurrl
transfected hONPs compared to the other restricted cell lines (Figure 6).
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pLNCX2

Non-Transfected
hOOPs

Figure 6. Histograms demonstrating the ratio of dopamine formation (pg/1 00111) to total

protein concentration (mg/ml) of cells transfected with pIRES-pitx3-nurrl, pLNCX2pitx3, pLNCX2-nurrl, pLNCX2-lmxla, pIRES, pLNCX2 and non-transfected hONPs.
HONPs transfected with pIRES-pitx3-nurrl exhibited the highest levels of intracellular
and extracellular dopamine production. Dopamine production and release were enhanced
in hONPs treated with the morpho gens.

32

4.

The effect of morphogens on tyrosine hydroxylase (TH) expression,

dopamine formation and release.

4.1.

HONPs were cultured in DFBNM along with RA

(1~M),

FN

(5~M)

and

either of two different sources (purities) of Shh for four days. Both Shh treatments
resulted in greater expression than in those cultured solely in DFBNM. TH expression
was greater in the cells that were treated with highly purified Shh than the commercial
product obtained from SIGMA when applied for same period oftime. (Figure 7).
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Figure 7. HONPs treated in DFBNM with a highly purified Shh(C) exhibited greater

reactivity to tyrosine hydroxylase (TH) than those treated with commercially available
Shh (B) for 3 days in the presence ofRA and FN.
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4.2.

HONPs treated with RAIFNS and highly purified Shh expressed

seemingly more intensive TH reactivity in the positive cells (Figure 7 A). Therefore, the
concentration of Shh was reduced to determine the lowest concentration of Shh that could
drive the hONPs towards dopaminergic neurons. In contrast to the response when a high
level ofShh was applied, the reduction of the Shh to O.02Smg/ml applied with RA (lIlM)
& FN (SIlM) did not produce an immediate response. The hONPs became TH positive

only after 18 hours of treatment with highly purified Shh; however, they were healthy
and maintained TH expression for longer periods. The application of RA and FN
promoted an even greater expression of TH (Figure 8 A). Therefore, the optimal
conditions for restricting the hONP lineage to dopaminergic neurons (under these defined
conditions) was determined to be DFBNM supplemented with RAIFN5ShhO.025 (Figure

8 B).
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Figure 8. A. HONPs cultured in DFBNM supplemented with O.025mg/ml of Shh, in the
presence or absence of retinoic acid (RA)(1IlM) and forskolin (FN)(5Ilm) for days
indicated. B. HONPs were tyrosine hydroxylase (TH) positive following 7 days treatment
with RAIFN5Shh.
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4.3 Stably transfected hONPs were treated with a cocktail of RA1FNSShhO.02S to
determine if a combination of genetic modification and morphogenic treatment would
increase intracellular and intercellular dopamine levels. Spent medium was collected 4
days after morphogenic treatment and concentrated to a 1iSO volume. The treated lineage
restricted hONPs were also collected. Dopamine E.I.A. was applied to both cell lysis
sample and concentrated medium. Dopamine formation efficiency was calculated as
previously described. HONPs transfected with plRES-pitx3-nurrl were the most efficient
population with respect to dopamine formation and release after morphogenic treatment
(Figure 6 A & B). Compared to intracellular and extracellular dopamine levels of the
lineage restricted hONPs in the absence of morphogens, dopaminergic expression was
greatly enhanced in the stably transfected hONPs in the presence of the combination of
Shh, RA and FN (Figure 6 A & B). These studies suggest that morphogenic treatment can
play an important role in dopamine formation and release by the lineage restricted
hONPs.

5.

Stably transfected and pre-transfected hONPs produce neurotrophins

(BDNF, CNTF and NT -3) at equivalent levels
The non- (pre)-transfected hONPs were found to produce neurotrophic factors such as
BDNF (S6.09±1O.24 pg/ml), CNTF (18.72±1.43 pg/ml) and NT-3 (24.87±6.S3pg/ml).
The stably transfected lines were examined to determine if lineage restriction to
dopaminergic neurons alters the synthetic capacity and activity of these neurotrophins; no
significant differences in intracellular neurotrophin (BDNF, CNTF, NT -3) levels between
transfected and non-transfected hONP lines were observed (P>O.Ol), indicating that
transfection did not alter neurotrophin synthesis. (Figure 9)
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Figure 9. Histogram demonstrating the neurotrophin levels in hONPs (pg/ml) transfected

with pIRES-pitx3-nurr1, pLNCX2-pitx3, pLNCX2-nurr1, pLNCX2-lmx1a, pIRES,
pLNCX2 and non-transfected NSFCs. Lineage restriction did not alter neurotrophin
production.
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D. Discussion

Parkinson's disease, as a neuronal degenerative disease, is characterized by loss of
specific dopaminergic neurons in substantia nigra (Hornykiewicz, 1973). Although a
variety of phannacological agents have been employed in the treatment of PD their
effects are transient. "Proof of concept studies" with embryonic adrenal medulla cells
(Fitzpatrick et aI., 2009) although ending in failure demonstrated the potential of a stem
cell based therapy. Recently substantial effort has been devoted to the search for a
suitable cell source for a cell replacement strategy for the treatment of PD. Many studies
have focused on the use of embryonic stem cells; studies utilizing embryonic cells
derived from mice or porcine were found to be functional in relieving PD like symptoms
in PD animal models (Yang et aI., 2010; Tonnesen et aI., 2011), and positive results
obtained from human oriented ES cells further advance the use and promise of stem cells
as a potential source for cell therapy for PD (Tatard et aI., 2007; Arenas, 2010; Blandini
et aI., 2010). However, these studies were all generally hampered by the significant side
effects due to the transplantation of ES cells, such as dyskinesias and/or the fonnation of
teratomas (Brederlau et aI., 2006; Arenas, 2010; Brundin et aI., 2010). Unfortunately, low
cell viability following transplantation, tissue compatibility, a limited of source and
ethical concerns further diminish the therapeutic utility of ES cells. In contrast, the use of
adult human olfactory epithelium derived progenitors, as a unique autologous cell
resource, which can be obtained with minimally invasive surgery can avoid these
negative factors and also eliminate the need for immunosuppression. The studies
described in this manuscript demonstrate that hONPs can be stably lineage restricted
under an optimized paradigm, so that they produce and release dopamine, which makes

42

them potential candidates for cell-based therapy for PD. Additionally, the genetic
modification didn't alter the capability ofhONPs to produce and release key neurotrophic
factors, which have the potential to support neuronal survival, as well as rescue
degenerating neurons. These factors can also provide permissive micro-environments that
may induce endogenous stem cell generation and differentiation. (Torp et aI., 2006; Hess
and Borlongan, 2008; Bao et aI., 2011).
In the present study, several factors have been observed to optimize the environment
for hONPs and facilitate their differentiation to dopaminergic neurons, including genetic
modification and morphogenic treatments, along with another emphasis, the capability of
hONPs to produce neurotrophic factors, which will all be discussed individually below.
1. Pitx3 and nurrl induce the DA neuron maturation synergistically.

The pitx3 gene belongs to the Pitx family of transcription factor genes and has been
shown to be required for the expression of TH, the precursor of dopamine, both in vitro
and in mice from EII.5 (Maxwell et aI., 2005). It has been reported that pitx3 is crucial
to the formation of SN and the specification and/or the survival of the subpopulation of
the DA neurons in striatum (Cazorla et ai., 2000; Haubenberger et aI., 2011; Reddy et aI.,
2011). The earlier studies suggest that pitx3 increased TH promoter induction in mouse
and rat cell lines, but not in human cell lines (Cazorla et aI., 2000; Lebel et aI., 2001).
However, human embryonic stem cells were employed in experiments to demonstrate the
regulation of TH expression by pitx3 (Hwang et aI., 2003b; Martinat et aI., 2006; Liu et
aI., 2009). These studies suggested that pitx3 is a key transcriptional regulator of genes
required specifically for the mesencephalic dopaminergic (mesDA) phenotype (Smidt et
aI., 1997; Liu et aI., 2009) and for TH expression (Maxwell et aI., 2005; Reddy et aI.,
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2011). Nurr1 is a member of the nuclear receptor super family of transcription factors
that is expressed in both developing and mature dopaminergic neurons in the central
nervous system in mice (Saucedo-Cardenas et ai., 1997). Previous studies have shown
that nurr1 is essential to both survival and differentiation of the ventral mesencephalic
dopaminergic precursor neurons (Smits et aI., 2003; Kim, 2011). Nurr1has also been
reported to be essential in the expression of TH, which is required for DA synthesis; and
for vesicular monoamine transporter 2 (VMAT2), which is related to DA storage; and
dopamine transporter (DAT), which is crucial for DA re-uptake (Smits et aI., 2003). In
addition, a recent study has shown that Nurr1 plays a previously unexpected role in
protecting TH positive neurons from neurotoxicity (Winner, 2008). Furthermore, nurr1 is
the only known transcription factor that is associated with the dopaminergic
neurotransmitter identity in mesDA neurons (Saucedo-Cardenas et aI., 1997). Therefore,
both pitx3 and nurr 1 have been shown to be crucial to the formation of SN and the
specification and/or the survival of the DA neurons in midbrain in rodents (Perlmann and
Wallen-Mackenzie, 2004b; Simeone, 2005; Krasnova et aI., 2011). The results obtained
in the present study indicate that overexpression of pitx3 and/or nurr1 promotes the
expression of DA neuron marker, TH in human adult olfactory epithelial-derived
progenitors in vitro. HONP lines that were stably transfected with pitx3 and/or nurr1 and
selected for 4 months, remained healthy and TH positive following 6 months cryostorage
in liquid nitrogen. Furthermore, the direct detection of dopamine production was also
evaluated. Lysates ofpitx3 or nurr1 transfected hONPs were dopaminergic as determined
by dopamine E.I.A. These results suggest that the transcription factors, pitx3 and nurr1,
not only function as a dopaminergic promoters in chick, mouse, or human embryonic
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cells (Saucedo-Cardenas et aI., 1997; Hwang et aI., 2003b; Courtois et aI., 2010; Katunar
et aI., 2010), but also participate in dopamine production in adult human olfactoryderived progenitors. Based on previous studies which focused on the regulatory function
ofpitx3 and nurrl in dopaminergic neuron promotion (Smidt et aI., 1997; Cazorla et aI.,
2000; Hwang et aI., 2003b; Smits et aI., 2003; Simeone, 2005; Vazin et aI., 2009) and the
studies described in this manuscript, we hypothesized that pitx3 and nurr1 may
collaborate to induce a higher efficiency of dopamine production in midbrain DA neuron
maturation. Previously a synergistic effect between pitx3 and nurrl on TH expression has
been reported, which appeared to be species dependent occurring in human but not in
embryonic murine stem cells (Lebel et aI., 2001; Martinat et aI., 2006; Messmer et al.,
2007). The current studies demonstrate that the simultaneous transfection of pitx3 and
nurrl into the hONPs produced higher levels of TH expression and dopamine production
than transfection of either of the individual genes. We evaluated the effect oftransfection
on the level of the precursor (TH) and final intracellular and extracellular dopamine
levels to confirm and compare the efficiency of the different transfected hONP lines.
Therefore, our data, in combination with published reports in rodents (Zetterstrom et aI.,
1997; Nunes et aI., 2003) and with human embryonic stem cells (Martinat et aI., 2006;
Jacobs et aI., 2009), indicate that pitx3 and nurrl cooperatively induce the maturation of
DA neurons. We extend the previous studies to show the feasibility of genetic
modification of adult human olfactory-derived progenitors to promote the generation of
DA neurons. These studies strongly suggest that the co-expression ofpitx3 and nurr1 will
enhance significantly the lineage restriction of adult human progenitors toward
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dopaminergic neurons which can be employed in cell-replacement paradigms for the
treatment of PD.

2. Treatment of hONPs with morpho gens enhances intracellular and extracellular
dopamine levels.
Human adult derived progenitors have the potential to differentiate along several
neural lineages in response to morphogenic signals in vitro (Zhang et aI., 2005). For
example, 11.6 (± 1.5) % of hONPs expressed TH following a 7 day treatment of
RAIFN5Shh (lflM RA, 5flM FN and 15nM Shh), indicating that a dopaminergic lineage
can be driven by exposure to these morphogens (Zhang et aI., 2006b). Sonic hedgehog
(Shh), (RA) and Forskolin (FN) have all been shown to be crucial developmental factors
that regulate neuronal specification and differentiation (Roisen et aI., 1972a; Roisen et aI.,
1972b; Ericson et aI., 1997; Novitch et aI., 2003; Kurauchi et aI., 2011; Trzaska and
Rameshwar, 2011). Shh has been shown to be required for the generation of ventral
midbrain motor neurons (Wichterle et aI., 2002; Ko et aI., 2009) as well as dopaminergic
neurons in rodents (Arenas, 2010; Blandini et aI., 2010; Krasnova et aI., 2011) and chick
embryos (Brundin et aI., 2010). This study suggests that Shh increases the expression of
TH and that the purity of Shh is an important determinant of TH expression. RA regulates
neuronal differentiation in embryonic stem cells (Bibel et aI., 2004; Moliner et aI., 2008)
and adult human neuronal progenitors (Hsieh et aI., 2004; Cooper et aI., 2010). RA has
several pathways through which it can effect cellular differentiation (Canon et aI., 2004;
Fathi et aI., 2010). FN is an adenyl cyclase activator that increases intercellular levels of
cAMP that can stimulate axonal elongation (Roisen et aI., 1972a; Roisen et aI., 1972b)
and induce embryonic rat/mouse motor neuron survival (Hanson et aI., 1998; Kobayashi
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et aI., 2011). Following the treatment of RA and FN, the progenitor nature of hONPs is
diminished, as characterized by a loss of nestin expression, and the presence of more
mature neuronal markers. In this study, a combination of highly purified Shh, RA and FN
was applied to the lineage restricted hONPs. The intracellular level of dopamine was
demonstrated to be significantly increased by this treatment. This result confirms and
extends the published data by showing that these morpho gens can increase TH expression
by progenitors obtained from adult humans (Zhang et aI., 2006b). Furthermore, following
a 4 day treatment of RAIFN5Shh, the dopamine level of the spent conditioned medium
was significantly enhanced, indicating that the morpho gens promoted the release of
dopamine, which is important for future studies transplanting lineage restricted hONPs
into PD animal models. Among all 4 lineage restricted hONP lines, those cells
transfected with pIRES-pitx3-nurrl produced and released the highest levels of dopamine
in the presence of Shh, RA and FN. This result is consistent with the analysis of the
lineage restricted cells in the absence of treatment with the morpho gens. This data further
supports the conclusion that hONPs transfected with pIRES-pitx3-nurrl are the most
efficient line in dopamine production studies to date, and therefore are likely candidates
for engraftment into an animal model of PD. Shh is secreted by the notochord and floor
plate at early stage of development (Echelard et aI., 1993), RA is detectable in the
midbrain of chick and mice embryos (Maden, 2002), and FN is highly concentrated in the
rat substantia nigra (Gehlert, 1986). The local distribution of these morphogens in situ
should influence the engrafted hONPs and may further support their survival and
dopamine release following transplantation. The higher level of dopamine released
following Shh, RA and FN treatment suggests their potential utility for cell-replacement
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therapy for PD. Previous studies on the non-human primate PD models, demonstrated
that the transplanted responsive human embryonic progenitor cells were still capable of
differentiation to DA phenotype within the micro-environment around the lesioned adult
host SN, an unexpected finding was that the engraftment also up-regulated an
endogenous progenitor population (Redmond et aI., 2007). The results of our studies
utilizing a paradigm that combines transfection and morphogen induced lineage
modulation highlight the potential therapeutic utility of olfactory epithelial-derived neural
progenitors as an autologous cell source for cell-based replacement strategies for patients
with Parkinson's disease.
3. Lineage restricted hONPs retain their capability to produce neurotrophic factors
It's been reported that neurotrophins such as BDNF, CNTF and NT-3 are crucial in
the recovery of primate and rodent models of Parkinson's disease (Redmond et aI., 2007;
Yoneyama et aI., 2011). BDNF is a member of the neurotrophin family which support the
maturation and survival of dopaminergic neurons in substantia nigra (Singh et aI., 2006;
Maia et aI., 2011). In the presence of BDNF, more TH positive cells can be found in
cultures of ventral mecensephalic tissue than in the absence of the neurotrophin (Braun et
aI., 2011; Maia et aI., 2011). NT-3 belongs to the same family ofneurotrophins as BDNF,
and has been shown to play a protective role in the degeneration of adult central
noradrenergic neurons in vivo (Sadan et aI., 2009; He et aI., 2010). CNTF has been
reported to rescue the degenerating striatal neurons in primate and rodent models (Fu et
aI., 2010; Edalat et aI., 2011). Furthermore, the absence of CNTF leads to the apoptosis of
motor neurons in adult mice (von Bohlen und Halbach and Unsicker, 2009; Li and Ding,
2010). Collectively these studies strongly suggest an important role for these
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neurotrophins in future therapeutic strategies for neurodegenerative diseases, including
PD, Alzheimer's disease and Huntington disease. Therefore, a cell population that can
produce neurotrophins could be an ideal source for cell therapy for these diseases. They
can provide protective micro-environments in vivo and prevent, rescue and or replace
neuronal degeneration. The pre-transfected hONPs were found to produce several
neurotrophins including BDNF and NT-3 when in a serum enriched medium (Marshall et
aI., 2006). The stably transfected lines were examined to determine if lineage restriction
to dopaminergic neurons or absence of serum alters the synthesis of these neurotrophins
since they play a role in neuronal survival, differentiation and maturation. As shown in
the results, the transfection of hONPs did not alter trophin production. The posttransfected hONPs produce BDNF, NT -3 and CNTF at equivalent levels with the pretransfected progenitors. Therefore, genetically modified hONPs can not only serve as
replacements of the dead or dysfunctional dopaminergic neurons but also can provide
protective micro-environments to help rescue dying or damaged neurons from further
degeneration and to enhance the endogenous progenitor populations. The stably lineage
restricted hONPs are unique populations with high potential for cell transplantation for
animal models of Parkinson's disease.
The long term goal of this study is to develop restricted hONP lines that will have
therapeutic utility in cell replacement strategies for patients with PD. The in vivo viability
and stability are important variables, especially considering the likelihood that with time
the engrafted population may die and require replacement. Therefore, experiments were
undertaken to determine the stability and viability of frozen stocks of transfected cells.
HONPs survived under the pressure of selection after removal from cryostorage and
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retained their ability to express TH, as well as produce and release dopamine and
neurotrophins, which further demonstrates the unique potential of these progenitors to
perhaps serve as an autologous cell source for cell-based strategies for the long-term
treatment of Parkinson's disease.
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CHAPTER III
PILOT STUDIES FOR THE EVALUATION OF THE IN VIVO
EFFECTS OF HONPS IN A PD ANIMAL MODEL
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Chapter II identified the most efficient dopamine-producing paradigm. This Chapter
described pilot studies that were undertaken to evaluate an animal model of PD in which
the in vitro results could be validated in vivo. Currently, there are two widely used
animal models of PD: the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced model
(MPTP) (Chang et aI., 2011; Yasuda et aI., 2011) and unilateral 6-hydroxydopamine (6OHDA) lesioned model of Parkinson's disease (Cai et aI., 2010). Studies with MPTP
involve mainly although not exclusively on primates (Hakura et aI., 1988; Burov Iu et aI.,
1995; Oiwa et aI., 2006). In contrast, the 6-0HDA model has been more popular in the
rodents (Matsukawa et aI., 2007; Cai et aI., 2010). Both models have been well
established and work equivalently in developing animal models of PD. The principal
advantage of using 6-0HDA for these studies is that this neural toxin is very sensitive to
dopamine agonists (Reyhani-Rad S., 2011). Since we had already determined the most
efficient dopamine-producing paradigm (Chapter II), we designed the studies to evaluate
the action of engrafted transfected hONPs on the 6-0HDA model of PD, along with the
cellular and medium controls. Initially, a toxin injection equivalent to a total of 20

~g

(Azzouz et aI., 2004; Massie et aI., 2010; Danielyan et aI., 2011) was employed. At this
level most of the animals started to exhibit Parkinsonian deficits within 3 weeks
following the injection; however, some of the animals behaviorally recovered with no
treatment as time progressed. This could be because not all of the dopaminergic neurons
degenerated or were severely damaged in response to the toxic injection, and spontaneous
recovery occurred. Therefore, in later experiments an increased toxin dosage was used to
make sure that no spontaneous recovery would occur. The total free base 6-0HDA
hydrochloride (Sigma H116) was increased to 28
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~g

(dissolved to the concentration of

3.51lg/IlI, with a total of 81l1, at 4 individual injection sites). As anticipated, no
spontaneous behavioral improvement was observed up to 27 weeks after the toxin
injection.
A. Selection of injection sites

The next step was to determine which location would be the most ideal area for the
neurotoxin injection, among the three most widely used sites: the Medium Forebrain
Bundle (MFB) (Zhang et aI., 2007), Substantia Nigra (SN) (Dymecki and Freed, 1989),
or the striatum (Danielyan et aI., 2011).
One hundred and thirty-eight female Spraque Dawley rats (Charles River,
Wilmington, MA, USA; 200-250g) were maintained under a 12-h light/dark cycle with
constant temperature and humidity. Food and water was available ad libitum. Twentyfour hours prior to surgery, animals were weighed and assigned to individual groups
(Striatum, MFB, SN) with ID numbers.
Prior to surgery the animals are anesthetized using ketamine (Hospire Inc. Lakeforest,
IL 60045) / xylazine (Ben Venue Lab. Bedford, OH 44146) 37.7mg/5mg/kg,
(O.lmlllOOg, IP). After anesthesia and 30 minutes before lesion, Desipramine (Sigma
D3900; 25mg/kg, 1M) was given to protect noradrenergic neurons from 6-0HDA
toxicity, and Pargyline (Sigma P8013; 50 mg/kg, 1M) to inhibit endogeneous monoamine
oxidase. A prophylactic dose of general antibiotics, penicillin (Butler, Dublin, OH 43017;
100,000 units/kg, 1M) was given to prevent infection. Twenty-eight micrograms of free
base 6-0HDA hydrochloride (Sigma H116) was injected into the animal brains according
to the three groups. Injection sites were located from the Bregma:
Striatum: AP: -1.3 mm, L: 2.6 mm, D: 5 mm;
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AP: -0.4 mm, L: 3.0 mm, D: 5 mm;
AP: 0.4 mm, L: 4.2 mm, D: 5 mm;
AP: 1.3 mm, L: 4.5 mm, D: 5 mm.
Medium Forebrain Bundle: AP: -4.4 mm, L: 1.2 mm; D: 7.8mm
Substantia Nigra: AP: -5.0 mm, L: 2.0 mm; D: 7.8 mm
Five milliliters of 0.9% saline was given to counteract any fluidlblood loss. Penicillin
(Butler, Dublin, OH 43017; 100,000 units/kg, 1M) and Buprenorphine (Bedford Lab,
Bedford, OH 44146; 0.02 mg/kg, 1M) were administrated for post-operation care for an
additional 2 days after surgery.
Three weeks after toxin injection, all animals were examined by using a rotation test
that is widely employed as a standard for evaluation of Parkinson's disease models
(Nikkhah et aI., 1993; Lei et aI., 2011). In the rotation test, amphetamine as a stimulant
was injected intraperitoneally, and rotation numbers were evaluated 15 minutes after the
injection. Three 15 minute segments were evaluated for a total of 45 minutes. Among
these three groups, the SN-injured model was eliminated because lower percentage of
animals were considered "qualified" models (over 6 turns in rotation test (described in
Chapter IV)) from this group, compared to the animals having received their toxic
injection in either the MFB or the striatum. The striatum was eventually selected as our 6OHDA injection site because multiple points of injections lead to more complete neural
degeneration. The striatum is a larger area, compared to the MFB, which will allow for a
more accurate placement of multiple injections.
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Table 1. Qualifying Model Rate

Qualifying Model Rate (>6 turns/min in Rotation
Test)
6-0HDA Lesion Site
20flg 6-0HDA

28flg 6-0HDA

MFB

9/24 (37.5%)

21128 (75%)

SN

116 (16.67%)

6/14 (42.85%)

Striatum

21/38 (55.26%)

20128 (71.42%)
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Table 1.

Three weeks after the 6-0HDA injection, the animals received

intraperitoneal amphetamine injection at 0.35mg/l00g body weight for rotation test.
The qualified rats (more than 6 turns/minute) will be utilized for the cell
transplantation and control animals., Three different toxin injection sites (MFB, SN,
and Striatum) were tried initially with the total of 20llg 6-0HDA. Only up to 55% of
the animals (Striatum group) exhibited qualifying rotation numbers. When the 6OHDA was increased to 281lg, more than 70% of the animals achieved qualification (
more than 6 turns / minute) in two regions, MFB and striatum, while only 43%
reached this level of deficit in the SN group. Therefore the SN as a neurotoxin
injection site for establishing the animal PD model was not utilized ..
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B. Determination of Cell Number for the Transplantation

Pilot studies were initialed to determine the optimal number ofhONPs for injection to
achieve the maximum recovery rate. PlRES-Pitx3-Nurrl transfected hONPs, which
previously (Chapter II) had been shown to be the optimized dopamine formation
paradigm, were transplanted to the qualified PD models, at their striatum: AP: -0.8 mm,
L: 2.8 mm, D: 5 mm; AP: 0 mm, L: 3.6 mm, D: 5 mm; AP: 0.8 mm, L: 4.4 mm, D: 5 mm
(Figure 9). Four different numbers of cells (5k, 10k, 15k, 50k) in six microliters DFBNM
were injected into the rats, which were then maintained for 16 weeks. One third of the
15k hONP-injected animals recovered in the behavioral tests, which was the highest level
of recovery, compared to the other concentrations (20% for 5k, 0 for 10k and 18% for
50k hONP transplanted animals). Therefore, it was determined that the striatum was the
optimal site of toxin injection for zero spontaneous recovery over time, and the most
ideal transplanted cell number for enhanced recovery was determined to be 15k.
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ell Transplantation Points

AP:+o.8mm, ML:+2.8mm, DV:+5.0mm
{

AP:+O.Omm, ML:+3.0mm, DV:+5.0mm
AP:-O.8mm, ML:+4.4mm, DV:+5.0mm

6-0HDA Injection Sites:
AP:+1.3mm, ML:+2.6mm, DV:+5.0mm;
AP:+O.4mm, ML:+3.0mm, DV:+5.0mm;
AP: -O.4mm, ML:+4.2mm, DV:+5.0mm;
AP: -1.3mm, ML:+4.5mm, DV:+5.0mm
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Figure 9. The four 6-0HDA toxin injection points were distributed both anterior and
posterior to the bregma, at: AP:+1.3mm, ML:+2.6mm, DV:+5.0mm; AP:+OAmm,
ML:+3.0mm, DV:+5.0mm; AP: -OAmm, ML:+4.2mm, DV:+5.0mm; AP: -1.3mm,
ML:+4.5mm, DV:+5.0mm. The three hONPs transplantation points were located in
between the toxic injury sites, at: AP:+O.8mm, ML:+2.8mm, DV:+5.0mm; AP:+O.Omm,
ML:+3.0mm, DV:+5.0mm; AP:-O.8mm, ML:+4Amm, DV:+5.0mm

59

Table 2. Cell Transplantation and Rotation Analysis
6-01IDA
Injection
Site

MFB

Injected CeO
Number

Rotation Numbers
3w after toxin
16w after CeO
Injection
Engraftment

Recovery
Rate

5k

904

865

5k

873

1204

5k

1733

464

5k

726

1024

5k

752

824

10k

1006

1568

10k

1391

1470

10k

1175

408

10k

1251

1487

10k

382

1344

15k

864

720

15k

1378

548

2 out of4

15k

1518

716

50%

15k

897

647

50k

502

1303

50k

714

1107

50k

1491

1632

50k

689

1367

50k

897

455

Medium Control

1172

719

Medium Control

654

454

Medium Control

1317

880

Medium Control

965

968

Medium Control

1385

1182

Medium Control

583

1047

Medium Control

604

1088
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1 out of5
20%

0

lout of5
20%

0

Striatum

15k

1058

1374

15k

13842

2383

15k

1235

500

15k

1500

399

15k

1279

1619

15k

466

1133

15k

1039

612

50k

721

1647

50k

600

1282

50k

1563

1953

lout of6

50k

938

1144

16.67%

50k

747

348

50k

1469

1766

Medium Control

639

1052

Medium Control

760

1500

Medium Control

621

1493

Medium Control

1834

1531

Medium Control

512

977

Medium Control

741

1432

Medium Control

1060

682

61

2 out of7
28.57%

0

Table 2. HONPs were transplanted into the qualified PD models. Different cell
concentrations were engrafted. A concentration of 15k hONPs produced the most
recovery as determined by the rotation test, compared to the other doses evaluated
Therefore 15k hONPs was used for the studiesdecribed in Chapter IV.. Red text
indicates the reduced rotation numbers after cell transplantation.
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B. Complimentary Behavior Tests

Most standard evaluation assays for 6-0HDA PD models rely primarily on the
rotation test. To supplement this evaluation we explored the utility of several
complimentary behavior tests including comer preference test, cylinder vertical climbing
test, stepping test and rope test, The comer preference test and cylinder vertical climbing
test will be further described and discussed in Chapter IV since they were adapted for the
in vivo studies.

1. Adjusting Stepping Test
Adjusting stepping test has been employed by some research groups to evaluate the
Parkinsonian symptoms in rat models (Olsson et aI., 1995; Kim et aI., 2002). The hindlimbs and one of the fore-limbs of animals were held by the investigator, with the other
forelimb exposed to a 90 cm rough wood board. The animal was moved slowly sideways
(5 seconds for 90 cm), twice in the forehand direction. The number of adjusting steps was
counted for both paws, and analyzed by comparing the left versus right limb usage along
within the distance along the board. A baseline study was performed and the normal rats
used both forelimbs equivalently when side-walking on the board, before the rats
received toxic injuries in their brains. This test was eliminated because this model seemed
less sensitive to this specific test than the other methods. The animals which showed
behavioral differences in other tests after toxin or cell injection did not exhibit an obvious
contrast in adjusting stepping test.
2. Rope Test
The animals were allowed to hang on a rope (diameter 3cm) through the use of their
fore-limbs and the time that they were able to remain hanging was recorded with the
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protection of a large basin underneath the animals. Most normal rats were able to hang on
with their fore-limbs for a relatively long time (over 1 minute). In contrast, the toxin
injured animals were too weak to support their body weight and fell into the protecting
basin within a few seconds after they were placed on the rope. However, several weeks
after this test was initiated, some animals started to learn how to pull themselves up and
they would stand on the rope instead of hanging with two limbs. This capability varied
between animals and was not related to the treatment group which made it difficult to
count or calculate the hanging time. Therefore, the rope test was eliminated from the
experiment as well because of the lack of consistent response within a given treatment
group.
Based on the pilot studies described above, we determined that the neural toxin, 6OHDA, would be injected at four points in the animal striatum, and 15k IPN transfected
hONPs would be transplanted thereafter. Besides the main standard for PD models,
amphetamine-induced rotation test, complimentary corner preference and a cylinder
vertical climbing test would be employed and further discussed in Chapter IV.
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CHAPTER IV
TRANSPLANTATION OF hONPs IN A RAT MODEL OF PD
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A. Introduction

Parkinson's disease (PD) is a major worldwide neurodegenerative disease whose
incidence has been steadily rising as the population longevity increases (Savica et aI.,
2010). PD is characterized by the extensive loss of functional dopaminergic (DA)
neurons in substantia nigra (SN) within the midbrain (Homykiewicz, 1973). This study
is to determine the therapeutic utility of hONPs in cell-based treatment for PD. In this
study, the hONPs were genetically modified by transfecting gene pitx3 and nurrl, after
which they were tyrosine hydroxylase (TH) positive even after four months of selection.
The pIRES-pitx3-nurrl (lPN) transfected hONPs can be cryo-stored in liquid nitrogen for
a minimum of six months, and retain their ability to produce and release dopamine, and
therefore have the distinct advantage of serving as stable resource for cell therapy for
Parkinson's disease (Soldner et aI.). Furthermore, the pre-transfected and post-transfected
hONPs have equivalent capacity to produce neurotrophins including brain-derived
neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), neurotrophin-3 (NT-3),
etc., all of which are important for the survival and function of dopaminergic neurons in
the CNS (Soldner et al.) (Singh et aI., 2006; Pessach and Notarangelo, 2011). Recent
studies also indicate that the neurotrophins have the potential to optimize the local
microenvironment of the damaged area, and thereby induce endogenous stem cells to
replace or rescue degenerating neurons (Lindvall and Kokaia, 2010; Kassis et al., 2011).
Therefore, genetically modified, as well as the non-transfected hONPs have a duel
potential to serve as replacements for dead or dysfunctional dopaminergic neurons and
also provide protective permissive microenvironments which can rescue dying or
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damaged neurons from further degeneration while simultaneously having the potential to
activate endogenous progenitors.
The object of the following study was to determine and evaluate the function of IPN
transfected and pre-transfected hONPs in a unilateral 6-hydroxydopamine (6-0HDA)
lesioned rat model of Parkinson's disease (Wright et aI., 2009). This model was
established in 1970 (Ungerstedt and Arbuthnott, 1970) and is widely used in the studies
related to Parkinson's disease (Hargus et aI., 2010; Rauch et aI., 2010; Danielyan et aI.,
2011). The human fibroblasts served as cellular controls, while the culture media alone

was employed as a vehicle control. In the pilot studies, two models with two different
toxin injection sites: the medium forebrain bundle (MFB) (Zhang et aI., 2007) and the
striatum (Danielyan et aI., 2011) were evaluated. Both models performed equivalently;
the striatum was selected as our injection site for the data shown in this manuscript.
Different cell numbers/ and vehicle volumes were transplanted into the animal models in
the initial studies and only the optimized concentration was applied in the experiments
discussed in this manuscript.
B. MATERIAL AND METHODS
1. Cell Preparations

plRES-Pitx3-Nurrl transfected and pre-transfected hONPs from the same patientspecific cell line were thawed from frozen stock that was maintained in liquid nitrogen
and cultured in minimal essential medium (MEM) with 10% heat inactivated fetal bovine
serum (FBS, GIBCO, Grand Island, NY) (10%OE) for one week, as described and
developed previously (Roisen et ai., 2001; Wang, 2011). Human skin fibroblasts (ACTT
crl-1836) were cultured under the same conditions. The hONPs were adapted to serum-
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free growth media via serial dilution of serum every day for 3 days until the cells were
finally cultured in DFBNM (DMEM/FI2 supplemented with 1% B27 and 0.5% N2 and
100 J..lg/ml gentamycin (GIBCO, Grand Island, NY)) on the day of engraftment. Cells

were detached and suspended in DFBNM and viability of the cells was analyzed using
0.4% trypan blue stain (GIBCO, 15250) according to manufacturer's protocol. Only
healthy living cells were counted and a concentration of 2500 cells/J..ll was prepared and
kept on ice.
2. Animal Model and Cell Transplantation
All animal care and surgical interventions were undertaken in strict accordance with
the Public Health Service Policy on Human Care and Use of Laboratory Animals, and
with the approval of the University'S Institutional Animal Care and Use Committee and
Institutional Biosafety Committee. The harvest of hONP was approved by the University
Institutional Review Board - IRB 521.01. An informed consent form was approved by
the IRB.
2.1. Establishment of Rotational Parkinsonian Rat Model
Female Spraque Dawley rats (Charles River, Wilmington, MA, USA; 200-250g) were
maintained under a 12-h light/dark cycle with constant temperature and humidity. Food
and water was available ad libitum. Twenty-four hours prior to surgery, animals were
weighed and assigned ID numbers.
Prior to surgery the animals were anesthetized usmg ketamine (Hospire Inc.
Lakeforest, IL 60045)1 xylazine (Ben Venue Lab. Bedford, OH 44146) 37.7mgl5mg/kg,
(O.lmlllOOg, IP). After anesthesia and 30 minutes before lesion, Desipramine (Sigma
D3900; 25mg/kg, 1M) was given to protect noradrenergic neurons from 6-0HDA
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toxicity, and Pargyline (Sigma P8013; 50 mg/kg, 1M) to inhibit endogeneous monoamine
oxidase. A prophylactic dose of general antibiotics, penicillin (Butler, Dublin, OH 43017;
100,000 units/kg, 1M) and was given to prevent infection.
Animal hair was shaved and the skin prepared w/betadine solution (Purdue Products
L.P. Stamford, CT 06901) at the surgical site. Animals were mounted in stereotaxic
apparatus, and the scalp was opened. A small burr hole was drilled into the skull with a
dental drill. For striatum injection, 28 Ilg of free base 6-0HDA hydrochloride (Sigma
H116) was dissolved immediately before use, in 8 III sterile saline containing 0.01 %
ascorbic acid and injected into the right striatum at the coordinates given by the brain
atlas of Paxinos and Watson (Paxinos and Watson, 1996). Injection sites were located
from the bregma: AP: -1.3 mm, L: 2.6 mm, D: 5 mm; AP: -0.4 mm, L: 3.0 mm, D: 5 mm;
AP: 0.4 mm, L: 4.2 mm, D: 5 mm; AP: 1.3 mm, L: 4.5 mm, D: 5 mm. Two III of 6OHDA solution was dispensed into each point with G#31 needle at a rate of21ll Iminute.
The needle was left in place for an additional 2 minutes to prevent backflow and then
slowly removed. The burr hole was filled with a piece of gel foam and the scalp was
closed. Five mL of 0.9% saline was given to counteract any fluidlblood loss. Penicillin
(Butler, Dublin, OH 43017; 100,000 units/kg, 1M) and Buprenorphine (Bedford Lab,
Bedford, OH 44146; 0.02 mg/kg, 1M) were administrated for post-operative care for an
additional 2 days post-surgery.
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Figure 11. Experimental equipment set-up and animal mounting. The surgery was
performed under the scope and the animal was mounted on the stereotaxic apparatus. The
6-0HDA solution was dispensed with G#31 needle in a 1Dill syringe.
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2.2. Assignment of Experimental Groups
The rotation test (described below) was the standard behavioral test used to evaluate
the performance of the rat models. Grouping of the qualified rats (2:6 rotations/min on
average, based on a total of 542±270 turns for 45 minutes) was performed before cell
engraftment. Animals were distributed to one of four groups with equivalent rotation
numbers. Three groups received unilateral (right, same side with 6-0HDA diffusion) cell
transplantation (IPN (N=39), pre-transfected hONPs (N=30), Human Fibroblast (N=7)
and one group received a vehicle injection (N =30). A separate group was designed as a
sham group, which was not administered anything throughout 24 weeks post toxin injury
(N=14).
2.3. Cell Transplantation
The rats were anesthetized, prepared and mounted in the same way as they were for
the surgery for toxin administration. A small burr hole was drilled into the skull with a
dental drill. Fifteen thousand cells in a total volume of 6 III were implanted into the
striatum of the animal in three specific locations (AP: -0.8 mm, L: 2.8 mm, D: 5 mm; AP:

o mm, L: 3.6 mm, D: 5 mm; AP: 0.8 mm, L: 4.4 mm, D: 5 mm). The injection in each
point was administered for 1 minute and the syringe was allowed to remain in place for
an additional 2 minutes after which it was withdrawn slowly to prevent reflux of the
solution. At the surgery site the skin was sutured with 5-0 silk stitches and 5ml 0.9%
saline was given intradermally. Penicillin (Butler, Dublin, OH 43017; 100,000 units/kg,
1M) and Buprenorphine (Bedford Lab, Bedford, OH 44146; 0.02 mg/kg, 1M) were
administered for post-operation care for an additional 2 days after surgery. Cyclosporine
(Bedford Lab, Bedford, OH 44146) was injected intramuscularly at the dosage of
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10mg/kg body weight every other day for at least 10 weeks starting from the day of
transplantation. All cellular control and non-engrafted animals received the same dosage
of cyclosporine at the same frequency.

3. Behavioral Analysis
3.1 Amphetamine-induced Rotation Test:
Three weeks after the initial 6-0HDA injections, the rats were stimulated with
amphetamine (3.0 mg/kg, IP, 3.0mg/ml, O.lmlllOOg.rat; Sigma A5880). A determination
of the number of rotations began 15minutes after drug injection to allow for drug
diffusion and continued for 45 minutes (recorded in a 3

x

15 minute pattern) afterwards.

On average, only the rats that rotated 6 or more turns per minute (for a total of 270
rotations in 45 minutes) were utilized for the remainder of the experiment. Those rats
were assigned randomly into controls or cell engrafted groups as described above. After
cell engraftment, the rotation test was preformed once every two weeks starting from the
3rd week, until 6 months.

3.2 Complementary Behavioral Tests:
Corner Test: Rats were placed in a right-angle corner of a box with the forelimbs
raised off the floor of the box. The direction that the rat turned to leave the corner was
recorded for 8 consecutive times. The number of left turns out of 8 trials were
summarized and averaged in each group.
Limb-use Asymmetry (Cylinder) Test: Rats were placed in a clear glass cylinder (30
cm tall by 22cm diameter). The number of wall contacts, made by their forelimbs (left,
right or both), was recorded for 3 minutes. The ratio of left/right usage was calculated
and averaged in each group.
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These complementary behavioral tests were performed once before the neurotoxin
injection for baseline and were continued once every week starting from the 2nd week
post treatment until 6 months after cell transplantation or medium administration.
4. Immunohistochemistry
Animals

were

deeply

anaesthetized

with

ketamine/xylazine

administered

intraperitoneally and perfused transcardially with a phosphate buffered saline (PBS) wash
followed by a 4% buffered paraformaldehyde (Sigma, P-6148) fixative. Brains were
removed and cryoprotected overnight in a 4% buffered paraformaldehyde fixative
followed by 20% sucrose (Sigma, S9378) at 4·C. The striatum of the animal was located
and dissected with a rat brain cutting block (slicer) and mounted in frozen Optimal
Cutting Temperature compound (Sakura, Torrance, CA). Coronal sections (12
micrometers) were cut on a sliding microtome (Leica, CM3050S). One out of six sections
were collected and stored serially at -80·C if not stained immediately. Sections were
reacted with an antibody against tyrosine hydroxylase (TH, Monoclonal, Sigma) using
the ABC method (Elite, PK-6100), with DAB (Vector, SK-4100) staining, passed
through an alcohol/xylene series and coverslipped with Permount (Fisher Scientific,
SP15-100). Some sections were employed for the immunofluorescence staining for
double labeling ofTH expression and anti-human localization.
S. Dopamine assay
The rats were terminated with an over dose of ketamine/xylazine 4 months after cell
or medium injection, and brains were removed immediately. The striatum of each rat
brain was dissected with a rat brain slicer and lysed in RIP A buffer (Sigma, R0278) with
a tissue grinder (Kimble Chase, 101020), in the presence of protease inhibitor (Sigma,
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P8340). Total protein of each sample was collected and dopamine production was
analyzed quantitatively with a dopamine enzyme immunoassay kit (Dopamine EIA,
Immuno Biological Laboratories, Inc.), according to the manufacture's protocol.
RESULTS
1. The Effect of cell engraftment on behavioral activity

Animals receiving hONPs exhibited reduced Parkinson-like behavioral deficits
following the engraftment of IPN-transfected and the matched pre-transfected cells into
the striatum of animals treated for over 3 weeks with 6-0HDA. In contrast, animals
transplanted with the medium vehicle or human fibroblasts remained unchanged from
neurotoxin-treated controls. Twenty-four weeks after engrafiment and 27 weeks after the
6-0HDA lesion, approximately 36% (14 out of 39) of the engrafted animals in IPNtransfected group exhibited improved behavioral recovery in a rotation test.

The

transfection of gene Pitx3 and Nurr 1 initiated the dopaminergic differentiation of the
hONPs and resulted in positive improvements which could be detected by the 6th week
post cell transplantation. On the other hand, 33% (10 out of 30) of the pre-transfected
hONPs, which were originally employed as a cellular control group, also had a reduced
rotation activity although the improvement required a longer post-engraftment period.
The IPN transfected animals initially exhibited improvement in week six post
engraftment, while the pre-transfected animals did not show any signs of behavioral
improvement until 12 weeks after transplantation. However, at the conclusion of these
experiments (27 weeks) no significant difference in level or degree of recovery was
detected between pre-transfected and post-transfected groups (P>0.05). Furthermore the
improved rotation levels were reduced to 43% of the initial levels in both the pre-
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transfected and post-transfected improved animals. Human fibroblasts were employed as
a cellular control to evaluate further the specific role of the hONPs in cell replacement
therapy for the 6-0HDA Parkinson model. Animals that received the fibroblasts had no
improvement in behavioral activity for the duration of this experiment which was 18
weeks post-engraftment. The recovery rate of the fibroblast engrafted animals was
significantly different from the IPN-transfected or pre-transfected hONP group (P<O.05);
there was no difference between the media control or fibroblast engrafted animals
(P>O.05). The medium controls never exhibited improved rotational deficits throughout
the 24 weeks following their treatment. In contrast, a significant difference was observed
between the hONPs (pre-andlor post-transfected) animals and the medium only control
andlor fibroblast engrafted groups (P<O.OI) (Figure 12 A, B).

Furthermore, the corner preference tests and cylinder vertical climbing tests were
performed for comparison with the rotational results. Baseline studies were performed
before the animals received their toxin lesion. The normal animals tended to turn left and
right equivalently in the corner test, while the injured animals, those receiving the
unilateral 6-0HDA turned toward the toxin injected side (right side in this study) much
more frequently than to the left. In contrast, the corner preference test demonstrated that
those animals that exhibited obvious reduction in the rotation test had reduced preference
and turned to both the left and right when faced into a corner. However, animals that had
no rotational improvement similarly had an overwhelmingly corner preference to the
right.

In contrast, the fibroblast engrafted and the medium only control animals

continued their right preference, turning to toward the right 7 times more than left (Figure
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13 A). In the cylinder vertical climbing test normal animals used their right and left front
paws equally against the glass wall as they reached for the top of the cylinder, while the
toxin injured animals had a strong preference to use their right more than their left front
paws. In this study, the animals that exhibited improved rotational deficits also had
improvements in cylinder vertical climbing test. Their left/right paw usage increased
from 0.1 to 0.4 over 24 weeks following engraftment, which was three times greater than
the human fibroblast transplanted or medium only treated controls (Figure 13 B).
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Figure 12. Thirty-five percent of the animals engrafted with transfected hONPs and
thirty-three percent of the animals engrafted with pre-transfected hONPs (non-transfected)
exhibited reduced rotation under the same level of amphetamine stimulation. In contrast,
animals in the control groups that received only the medium or human fibroblasts had no
reduction in rotational activity (A). A significant difference was observed between the
hONP engrafted (transfected or non-transfected) and medium control group (P<O.OI). In
contrast, there was no significant difference between the transfected and non-transfected
engrafted groups, nor was there a difference between the fibroblast and the medium only
control groups (P>O.05) (B). Error bars indicate standard deviation.
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Figure 13. The comer preference test (A) and the cylinder vertical climbing test (B)

showed consistent results with the amphetamine induced rotation test. The animals which
reduced in rotation numbers also exhibited behavioral improvements in comer and
cylinder tests. In the comer test, the left tum numbers tended to be 50%, meaning
equivalent left versus right preference when randomly facing a right comer in the preand post-transfected hONP il1iected animals. In contrast, in the medium and the fibroblast
controlling group, the animals will mostly tum to the toxin injected side (right side in this
study). In the cylinder vertical climbing test, the hONP transplanted animals use their left
paws three times more than the medium or fibroblast implanted animals. Error bars
indicate standard deviation.
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2. Transplanted hONPs Promote TH Expression in the Toxin-injured Sites

Unilateral treatment of the rat striatum with the neurotoxin 6-0HDA destroyed all TH
positive cells after three weeks as demonstrated by the lack of immunoreactivity in the
area of treatment. Furthermore, no detectable spontaneous recovery of TH positive cells
occurred throughout 24 weeks post-neurotoxin injection nor was TH positive
immunoreactivity observed in the toxin treated regions of the sham operated
controls.(Sham group, Figure 14 A-D) nor was it detected in the human fibroblast or
medium only injected control groups (Figure 15 C, D). The left sides of the brains, which
did not receive the toxin injury, expressed TH in the striatum, while the right side
striatum did not demonstrate any TH regeneration over 27 weeks after the toxin injection,
nor did it restore any in the cellular or medium controls. In contrast, both the pre- and
post-transfected hONP engrafted animals, which improved in the behavior tests,
exhibited greater TH expression in sections of their striatum, compared to the controls
(Figure 15 A, B).
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Figure 14. Dopaminergic neurons degenerated in the 6-0HDA lesioned side (right) of

the animals throughout the time line, and did not recover spontaneously (A-D). TH
expression started to be dismissed since the 3rd week after 6-0HDA injection, and there is
no spontaneous restoration ofTH up to 24 weeks after toxic injury.
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Figure 15. More dopaminergic neurons were found in the lesioned sites of animals

engrafted with transfected and non-transfected hONPs (A, B), while the medium or
human fibroblast injected controls had a significant deficit of dopaminergic neurons (C,
D).
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3. HONPs remain intact and TH positive for a minimum of 6 months after

transplantation
Twenty-four weeks after engraftment, dopaminergic neurons were detected in the toxininjured striatum of the hONP transplanted animals (Figure 16 A, B). The engrafted hONP
population remained intact and TH positive for a minimum of six months in vivo. These
cells strongly resembled multipolar neurons which were characterized by long processes
that frequently passed out of the plane of focus. (Figure 16 C, F). Furthermore, TH
positive processes were found well beyond the injection sites (Figure 17 A, B). Cell
bodies and processes that expressed TH were detected 800llm away from the initial
implantation area. As stated above, about 36% of the animals, that received hONP
injection, recovered in both post-transfected and pre-transfected groups. A quantitative
study was performed and significant differences in TH positive cell numbers were
detected between transfected recovered (T-Recov) and transfected non-recovered (TNoRecov) animals (P<O.05) and between pre-transfected recovered (PreT-Recov) and the
pre-transfected non-recovered (NoPreT-NoReov) animals (P<O.05). No significant
differences between the recovered transfected and recovered pre-transfected animals
were observed (P<O.05). Similarly no differences were found between the non-recovered
animals of these two groups (P>O.05) (Table 1). No TH positive cells were observed in
the toxin-injured striatum of the human fibroblast, the medium only injected, or the sham
controls. Human fibroblast cells were not detectable 4 months after transplantation.
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Figure 16. IPN-Transfected hONPs (A,-C) and the pre-transfected hONPs (D-F) were
intact and TH positive 24 weeks after the cell engraftment. High magnification confocal
microscopy reveals that both the transfected and non-transfected hONPs had TH positive
processes (C, F).
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Figure 17.

IPN-Transfected hONPs (A) and the pre-transfected hONPs (B) were

observed intact and TH positive 24 weeks after the cell engraftment, 800llm beyond the
initial injection sites.
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Table 3. P values of the comparison of the cell numbers in animal striatum
P Value

TRecov

TRecov

TNoRecov

PreTRecov

0.008

0.63

PreTNoRecov

TNoRecov

0.08

0.11

PreTRecov

0.63

0.009

PreTNoRecov

0.009

0.11
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Table 3. There was no significant difference in cell numbers between the recovered
transfected and the non-transfected hONP engrafted animals (P>O.l) or between the nonrecovered transfected and non-transfected hONP transplanted animals, (P>O.l), However,
there was a significant difference between the behaviorally improved and the
nonrecovered animals (P<O.05). Definition of abbreviations TRecov: Transfected
Recovered;

TNoRecov:

Transfected

Non-recovered;

Recovered; PreTNoRecov: Pre-transfected Non-recovered.
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PreTRecov:

Pre-transfected

4.

Analysis of the dopamine levels.

Dopamine enzyme immunoassay was employed 4 months after toxin injury to detect the
dopamine level in the striatum sections of half brains. The left half brains that never
received 6-0HDA injuries contained 1.44±0.68 dopamine (pg)/total protein (ig) (D/TP),
which is fourteen times greater than the toxin injured and medium only injected brains
(0.11 0.04 D/TP ). The recovered animals from pre-transfected and post-transfected
groups had D/PT levels of 0.27±0.07 (pg/ig) and 0.41±O.l1 (pg/ig) respectively. The

D/PT levels of pre-transfected non-recovered animals averaged at 0.11±0.03 (pg/ig),
while the post-transfected non-recovered averaged level was 0.13±0.03 (pg/ig). The
behaviorally improved animals exhibited higher levels of dopamine compared to the nonrecovered or the medium only controls. The dopamine level in the left side brains, which
never received toxin injection, was significantly higher than all the right sides. There was
no significant difference (NS) between the transfected recovered and non-transfected
recovered, or the transfected non-recovered and non-transfected non-recovered animals.
However, the dopamine levels in the treated brains of recovered and non-recovered
animals were statistically different from each other (Figure 18).

94

Dopamine Analysis in Animal Brains

i
_

2.5 ~----------------------------------------------------------------------------~

I
2 ·

c:

**
IC------~-----

I

Qj

~

Q..

~
~

15

1

..t.

V)

**

::::::..

0\

1

E
c:

0, 1

~

**
r--------

c:

'E

~ 0.5

NS

8
o

LEFT

IPN R-R

NTR-R

IPN NR-R

NT NR-R

MediumR

Figure 18. The left side of the brain that never received the toxin injection retained the

highest dopamine level and was significantly different from all right side brain levels.
Significant difference was observed between the recovered and non-recovered the
animals (P< 0.05, **). However, There was no significant difference (P>O.l, NS)
between transfected recovered and non-transfected recovered, or transfected nonrecovered and non-transfected non-recovered animals.
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C. DISCUSSION

Currently, the etiology and cure for Parkinson's disease remam unknown
(Hornykiewicz, 1973). Although the disease is characterized by the degeneration of
dopaminergic neurons in a region of the midbrain known as the substantia nigra, the
underlying mechansisms have been elusive. Pharmacological agents, although widely
used, only transiently relieve symptoms, losing their effectiveness with prolonged use
(Lloyd and Hornykiewicz, 1973; Sharpe et aI., 1973). A considerable level of proof of
concept research aimed at developing a cell replacement therapy is ongoing (Anderson
and Caldwell, 2007; Parish et aI., 2008). Early studies included the transplantation of
embryonic tissues such as mesencephalic tissue (Piccini et aI., 2000; Freed et aI., 2001),
fetal nigral cells (Nikkhah et aI., 1994; Kordower et aI., 1998), or ventral midbrains
(Mendez et aI., 2005). With the relief of Parkinsonian symptoms, these trials raised
several concerns: 1. The lack of donor tissue; each patient receiving this surgery required
3-5 fetal brains (Freed et aI., 2001), which increased the risk of bacterial or viral
infection. 2. Even with well-experienced surgical team, the outcome varied with each
individual. 3. Dyskinesia eventually occurred in a significant proportion of patients
(Barker and Kuan, 2010; Lane et aI., 2010). Therefore, an alternate expandable source for
dopaminergic cells has been a major research focus (Daadi, 2002; Lindvall et aI., 2004).
Stem cells represent a potential population for cell-replacement treatment of Parkinson's
disease due to their capacity for self-renewal and ability to differentiate into other cell
types (Lindvall et aI., 2004). Human embryonic stem cells were one ofthe first stem cell
populations employed in a PD model, and significant decrease in rotation tests from pretransplantation levels following cell transplantation have been reported (Bjorklund et aI.,
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2002; Correia et aI., 2005; Brederlau et aI., 2006). A large number of studies focused on
iPSCs, which were derived from human fibroblasts (Takahashi and Yamanaka, 2006;
Takahashi et aI., 2007), human or rat primordial germ cells (Shamblott et aI., 1998; Okita
et aI., 2007; Hamanaka et aI., 2011), or mammalian embryos (Martin, 1981; Nichols et
aI., 1998).

These cells promoted behavioral recovery when transplanted into

Parkinsonian animal models (Hargus et aI., 2010). However, like embryonic stem cells,
in most cases (50% or more) they generated teratomas within 6 weeks (Arnhold et aI.,
2004; Hedlund et aI., 2007; Chang et aI., 2011).
The long-term goal of the present study was to find a stable, non-tumorigenic cell
source that could be used in a cell-based therapy for Parkinson's disease. Our lab
developed methods to isolate and expand neural progenitors from human adult olfactory
epithelium (31). The epithelial tissue was obtained via endoscopic biopsy from the
olfactory region of the nasal cavity without invasive surgery or significant injury to the
donor. The cells were then cultured for 8-12 weeks until the progenitors (hONPs) were
obtained as previously described (Kordower et aI., 1998; Winstead et aI., 2005). The use
of hONPs that can be obtained from the patient and then returned to the patient would
eliminate ethical concerns as well as the need for immunosuppressive agents since they
would be autologous. Previous studies demonstrated that hONPs can differentiate into
neurons in response to their local environment (Zhang et aI., 2005; Zhang et aI., 2006).
The hONPs were lineage restricted to dopaminergic neurons by transfection with the
Nurrl and Pitx3 genes, which worked synergistically in this process (Wang, 2011).
Furthermore, hONPs produce a variety of neurotrophic factors in vitro (Marshall et aI.,
2005) and in vivo following their engraftment (Lu et aI., 2011). Recent studies have
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shown that hONPs can act as biological mini pumps releasing neurotrophic factors that
create a permissive environment for regeneration (Lu et aI., 2011). Furthermore, several
of the released neurotrophins including BDNF CNTF and NT -3 have been shown to be
crucial in the recovery of primate and rodent models of Parkinson's disease (Redmond et
aI., 2007; Yoneyama et aI., 2011). The pre-transfected hONPs were found to produce
many of these essential neurotrophins including BDNF and NT-3 even when in a serum
enriched medium (Marshall et aI., 2005). In this study transfection ofhONPs did not alter
neurotrophin production. The post-transfected hONPs produce BDNF, NT-3 and CNTF
at levels equivalent to the pre-transfected progenitors. Therefore, genetically modified
hONPs can not only serve as replacements for the dead, dying or dysfunctional
dopaminergic neurons but they also have the potential to provide a protective premissive
microenvironment to help rescue dying or damaged neurons from further degeneration
and to enhance the endogenous progenitor populations. Transfected and pre-transfected
populations support a dual mechanism of synthesis and release of both dopamine and
neurotrophins which collectively have the capacity to enhance the deteriorating, nonpermissive environment created by the 6-0HDA administration in the Parkinsonian rat
model.

In contrast, the fibroblast engrafted cellular controls and those animals that

received medium only as a vehicle control showed no improvement which reflected the
non-permissive environment created by the neurotoxin.

The amphetamine-induced

rotation test was applied as the main standard. This procedure has been widely used to
evaluate this Parkinsonian model (Nikkhah et aI., 1993; Lei et aI., 2011). However, a
comer preference and vertical climbing assessment were used to further support the
results of the rotational studies. Once the rotation numbers decrease consistent with the
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literature improvement in Parkinsonian deficits were noted (Anderson and Caldwell,
2007; Vidailhet, 2011). Furthermore, when the rotations were reduced to half of the
starting level, the rat was operationally considered partially recovered. We predicted that
animals that received IPN-transfected cells would recover behaviorally, while the nontransfected hONPs implanted animals would not recover, or at best would have less
recovery compared to the transfected group, because the non-transfected hONPs
produced less dopamine than the transfected hONPs in vitro. However, as described
above, 35% of the animals that received IPN-transfected cells behaviorally recovered
according to the rotation test. Surprisingly, 33% of the animals engrafted with nontransfected hONPs exhibited reduced rotation numbers equivalent to those engrafted with
the IPN-transfected cells.

There was no significant difference in the final level of

recovery between the two groups. The difference between the two groups was that the
non-transfected cell-injected animals exhibited a rotational reduction 6 weeks later than
the IPN-transfected progenitor-implanted rats on average. This might reflect the time
required for the non-transfected hONPs to differentiate into dopaminergic neurons and or
to affect the local micro-environment and thereby stimulate autologous stem cell
populations to form dopaminergic neurons. It has been reported that the trophic factors
act neuroprotectively in Parkinson's disease models (Torp et aI., 2006; Kong et aI., 2008).
We therefore hypothesized that the neurotrophins produced by transfected and nontransfected hONPs would play an essential role in recovery from Parkinson's disease.
Thus neurotrophic molecules could have a dual role; "cellular protection" in addition to
cellular replacement for the dopaminergic cells.
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Behavioral recovery has also been reported in Primate Parkinson's models in
response to the human neural stem cell transplantation; these animals exhibited
behavioral improvement during a 60 day period after stem cell transplantation.(Redmond
et aI., 2007; Redmond et aI., 2010). The authors of these studies suggested that the
Parkinsonian primate CNS may benefit from replacement of degenerating DA neurons by
differentiated human stem cells, and/or the trophic, protective, and guidance effects of
stem cell-derived progeny which is consistent with our results. Other studies employing
human embryonic (Redmond et aI., 2010) or adult (Bjugstad et aI., 2008) stem cells in the
6-0HDA rat model also reported some behavioral recovery of the Parkinsonian deficits
following cell transplantation. These authors suggested that it was likely that the grafted
human stem cells may be protective against the toxicity from the 6-0HDA in rats'
striatum. Collectively these support our hypothesis that the behavioral recovery in the
hONP transfected animals may be the result of two separate but complimentary actions:
the trophin-enriched protective microenvironment and or the replacement dopaminergic
neurons.
A series of control groups were included to demonstrate that the behavioral recovery
was specifically due to the engrafted pre- and post-transfected hONPs rather than the
toxin-Iesioned environment alone, with the medium or with the injection of a non hONP
cell types. A sham group was included with the same dosage and location of 6-0HDA
injection, and evaluated for the entire 27 weeks. Immunohistochemistry was employed to
determine if the DA neurons would be restored in the sham, medium, or cellular control
groups. No TH expression was detected in any of the control groups, 24 weeks after
cell/medium engraftment, which was 27 weeks after the toxin injection, indicating that

101

the microenvironment of the lesioned sites can only support DA neuron development
induced by the hONPs. Therefore, the hONPs represent a unique cell type for cellmediated therapy of Parkinson's disease, with the ability to differentiate into
dopaminergic neurons and to stimulate the microenvironment for host stem cell
activation in situ.
Immunohistochemistry demonstrated that both the transfected and non-transfected
hONPs survived and remained TH positive for the duration of the experiment (a
minimum of 24 weeks after transplantation, indicating that these cells have the long-term
potential to provide dopamine and neurotrophin rich environments. In contrast, the
human fibroblasts were not detected 24 weeks after the engraftment which further
demonstrates the specific stability and utility of the hONP population. Furthermore, the
TH positive hONPs were observed as far as 800 /lm from their engraftment site,
demonstrating that hONPs can migrate in the local environment of the 6-0HDA lesioned
striatum which is essential to cell intergration. Similar results were reported by other
groups using human embryonic stem cells and iPSCs (Svendsen et aI., 1997; Bjugstad et
aI., 2008; Zhu et aI., 2009; Wolff et al., 2011), which survived and promoted
improvement in the behavior tests in the animals with Parkinsoian symptoms. Bjugstad et
ai. reported that the neural stem cells isolated from the human fetal telencephalon
migrated along the nigrostriatal pathway 4 months after transplantation in an adult
monkey in an alternate, I-methyl 4-phenyl 1,2,3,6-tetrahydro pyridine (MPTP) model of
Parkinson's disease. More cells were detected along the pathway 3 months post
engraftment, demonstrating that after transplantation, the hNSCs did not remain entirely
in the injection site, but migrated along certain pathways (Bjugstad et aI., 2008). Studies
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with iPSCs engraftment in a MPTP lesioned mouse model demonstrate that these cells
also migrate from the site of transplantation in the striatum, to the site of lesion,
localizing in the substantia nigra (Wolff et aI., 2011). Collectively these studies are in
agreement with the present study and demonstrate significant cell migration after
transplantation, although different species and models were employed.
It has been reported that the PD models which were transplanted with ESCs or iPSCs

eventually developed teratoma and died within 6 weeks for ESCs (Freed et aI., 2001;
Arnhold et aI., 2004; Hedlund et aI., 2007), and 7-9 weeks for iPSCs (Kong et aI., 2008;
Hwang et aI., 2010) after transplantation. In the present study with hONPs, no tumor
formation was detected 24 weeks after cell transplantation, indicating that the hONPs
represent a more stable, lineage committed population and thus are more suited for cell
replacement-therapy for Parkinson's disease. Furthermore, the hONPs can be cryostored
in liquid nitrogen without loss of viability for future engraftment should serial treatments
become necessary (Wang, 2011).
Dopamine EIA was applied to detect the dopamine level in animal brains. It has been
shown that the brains of Parkinsionian models have decreased dopamine levels.
(Santaniello et aI., 2010). In the hONPS engrafted brains the dopamine levels in the
behaviorally recovered animals were higher than in animals without behavioral
improvement suggesting that the hONPs were functional and that the recovery was in
part the result of the increased dopamine levels. Other groups also reported that
intracranial transplantation with iPSCS resulted in a significant improvement of striatal
concentrations of dopamine in the behaviorally recovered MPTP mouse model of PD as
measured by high-performance liquid chromatography (HPLC) (Wolff et aI., 2011)
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which further supported the likelihood that the observed behavioral improvement was the
result of the increased dopamine as well as neurotrophin support provided by the
engrafted hONPS.
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CHAPTER V

GENERAL DISCUSSION,
SUMMARY AND FUTURE DIRECTIONS
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Parkinson's disease (PD) is one of the leading neurodegenerative disorders in the
world (Anderson and Caldwell, 2007); as the population longevity increases the
incidence will further expand. (Savica et aI., 2010). It is believed that the cause of PD is
related to the loss of dopaminergic neurons in Substantia Nigra (SN), a small area in the
midbrain (Hornykiewicz, 1973b). This degeneration results in less dopamine, which
functions as a neurotransmitter, in the nigrostriatal pathways (Hornykiewicz, 1973a).
Lower levels of dopamine result in a variety of movement disorders (Herrero et aI., 2011).
Dopamine, when given as a medication, is not able to pass the blood brain barrier.
Therefore the oral L-dopa, a precursor in dopamine synthesis, can pass the blood-brainbarrier and has served as the principle and traditional treatment for PD (Bidet-Ildei et aI.,
2011). However, L-dopa does not provide long-term relief because: 1. The patient

become less sensitive to the medicine over time (Callaway, 2011); 2. The L-dopa does
not prevent degeneration of the dopaminergic neurons (Lang and Lozano, 1998; Sheng et
aI., 2010); 3. It usually leads to severe dyskinesia after several years of use (Friedman,
1985; Wedekind, 2005). Therefore, an alternative therapy is definitely needed.
Cell replacement therapy has become a major focus with promise for a future
treatment of patients with Parkinson's disease. The concept of this strategy is to replace
the degenerated or unhealthy neurons (dopaminergic neurons) with the new functional
cells. Therefore, many researchers are involved in the search for an ideal cell source for
transplantation into PD models (Lindvall et aI., 1990; Olanow et aI., 2001). Early studies
that employed neural cell grafts obtained from the human fetal ventral mesencephalic
(VM) dopaminergic neurons, successfully relieved the Parkinsonian symptoms following
transplantation (Lindvall et aI., 1988; Madrazo et aI., 1988; Lindvall et aI., 1992;
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Borlongan, 2000; Ganser et ai., 2010). However, treatment of a single patient with this
procedure required 4-5 fetal brains, because of the low neuronal viability of these fetal
cells once they were transplantation (Mendez et ai., 2005). Furthermore, this treatment
required immunosuppressive therapy because of the numerous donor tissues (Lindvall et
ai., 1990).

In comparison even significantly lower numbers (15 K vs lOOK) of

transplanted hONPs can be detected 24 weeks after engraftment; the cells remain TH
positive indicating their high viability and health in vivo. More importantly, the hONPs
are unique having an autologous source (Roisen et ai., 2001), which means that the PD
patient can be both the donor and the recipient. This tissue source also eliminates the
ethical concerns associated with the use of fetal tissue, the long waiting list for a matched
donor and the need for immunosuppressive procedures. The hONPs are stably isolated
progenitors and can be stored in liquid nitrogen for years, or cultured in vitro for over 200
passages (2 years) no matter the gender or age of the patient. The telomerase activity of
hONP cultures remained relatively constant over an in vitro period of 6 weeks to 2 years
which corresponded to several hundred passages (P>0.05). The hONPs exhibit a
relatively consistent level of metabolic activity as well; no differences (P> 0.05) in
ornithine decarboxylase activity were found irrespective of the donor age, sex or the time
in culture (Marshall et ai., 2005). The high stability of these cells makes them an ideal
source for experimental and clinical trials since they can be obtained from any patient.
The hONPs can be lineage restricted to dopaminergic neurons by genetic
modification with gene Pitx3 and Nurr1, as well as the treatment with a combination of
morphogens (RA, FN and Shh). When transfected with double genes Pitx3 and Nurrl,
which have been shown to be essential in survival and development of dopaminergic
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neurons in embryonic mouse/chicken (Saucedo-Cardenas et aI., 1997; Cazorla et aI.,
2000; Haubenberger et aI., 2011; Reddy et aI., 2011), higher TH expression and increased
dopamine production were observed compared to the non-transfected or the results
obtained with the single gene transfected paradigm. This observation is consistent with
reports from other groups that report a synergistic effect between Pitx3 and Nurr1 on TH
expression in embryonic human or embryonic murine stem cells (Martinat et aI., 2006).
However, this is controversial in human or murine embryonic stem cells with some other
groups claiming the opposite conclusion (Messmer et aI., 2007). Our results suggested a
synergetic effect of Pitx3 and Nurr1 in development of dopaminergic neurons in adult
human stem cells. The transfected hONPs were cultured under the pressure of G418
selection for an extensive 4 months after the transfection to ensure the pure transfected
populations were obtained. After the initial four month-selection, the transfected hONPs
were stored in liquid nitrogen for an additional four to six months after which they were
found to remain TH positive and to produce dopamine when removed from the
cryostorage. This result suggested that the hONPs were stably transfected and
continuously remained the dopaminergic in nature. This level of stability will allow the
option of multiple injections over time in future studies should they become necessary
when hONPs are employed in clinical trials. Furthermore, dopamine production by
hONPs has been shown to increase when treated with a combination of morphogens
(Zhang et aI., 2006; Wang, 2011). Sonic hedgehog (Shh), (RA) and Forskolin (FN) have
all been shown to be crucial developmental factors that regulate neuronal specification
and differentiation (Roisen et aI., 1972a; Roisen et aI., 1972b; Ericson et aI., 1997;
Novitch et aI., 2003; Kurauchi et aI., 2011; Trzaska and Rameshwar, 2011). A
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combination of 0.025 mg/ml highly purified Shh applied with RA (lflM) and FN (5flM)
increased the TH expression and dopamine production maximally indicating that the
morpho gens promoted the release of dopamine, which is important to note when planning
future transplantation studies into PD models with morphogen treated and lineage
restricted hONPs.
Some neurotrophic factors, such as BDNF, CNTF and NT-3, have been shown to be
essential to the behavioral recovery in the primate and rodent models of Parkinson's
disease (Redmond et aI., 2007; Yoneyama et aI., 2011). Therefore, a cell population that
can produce these neurotrophins could be an important source for cell therapy for this
disease. They can provide protective micro-environments in vivo and, rescue and/or
provide a population to replace lost or degenerating neurons. Pre-transfected hONPs were
found to produce several neurotrophins including BDNF and NT-3 when in a serum
enriched medium (Marshall et aI., 2006). In a previous study we demonstrated that
transfection did not alter the capability ofhONPs to produce these neurotrophins (Wang,
2011). Therefore, the Pitx3 and Nurrl transfected hONPs can not only serve as
replacements of the dead or dysfunctional dopaminergic neurons but also can provide
protective micro-environments that may help rescue dying or damaged neurons from
further degeneration and to enhance the endogenous progenitor populations. The
multiphasic action of transfected hONPs could allow them to function as an ideal source
for cell therapy for the treatment of PD.
There are as many research groups usmg stem cells as there are different
transplantation sources, including embryonic stem cells (ESCs) (Lonardo et aI., 2010;
Yang et aI., 2010) and induced pluripotent stem cells (IPSCs) (Hargus et aI., 2010; Chang
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et aI., 2011). Stem cells are an attractive potential source because of their unlimited
capacity for self-renewal and the potential for lineage restriction (maturation) into one or
more specific cell types, in response to their origin and the micro-environmental signals
that they receive (Lindvall et aI., 2004; Hwang et aI., 2010).

Positive behavioral

improvements with PD animal models have been achieved with transplantation of both
ESCs and IPSCs, however, more than half of the animals that received either the ESCs or
IPSCs eventually developed teratomas within 9 weeks post transplantation (Arnhold et aI.,
2004; Takahashi and Yamanaka, 2006; Hedlund et aI., 2007). In our study, the animals
were maintained as long as 24 weeks after the cell engraftment and no tumorgenesis was
observed. It has been reported that the risk of tumor formation can be reduced by predifferentiation of the stem cells in vitro, before the transplantation (Brederlau et aI., 2006;
Li et aI., 2008). However, it has been demonstrated that pre-differentiated stem cells are
more difficult to adapt to the host environment, and will therefore more likely to be
rejected by the host (Dressel, 2011). This conflict highlights a bottle neck in stem cell
transplantation strategy. In the present study, hONPs were shown to be unique because
the undifferentiated pre-transfected cells were as effective as their lineage restricted
counterparts, indicating that no genetic manipulation was needed for hONPs to serve as
an effective source for a cell based therapy for PD. As previously discussed several
additional benefits are also gained through the use of hONPs including the elimination of
the ethical and practical concerns due to transfection of animal genes into human cells.
Furthermore, the number of cells needed when either ESCs or IPSCs sources were used
in PD animal models (100,000-160,000) (Arnhold et aI., 2004; Brederlau et aI., 2006; Cai
et aI., 2010; Hargus et aI., 2010) was eight times greater than the number of hONPs

110

(15,000) required to achieve a positive behavioral recovery, which further supports the
unique advantage of hONPs over other cell types and opens the possibility of multiple
injections over time should they become necessary.
Immunohistochemical localization of both the transfected and non-transfected hONPs
demonstrated intact and TH positive cells in the behaviorally improved animals 24 weeks
after the transplantation. Significant fewer cells were observed in the non-recovered
animals in both groups compared to the animals with improved behavioral tests. In the
future it will be essential to define the time course of the degeneration of engrafted
hONPs so that it can be minimized or followed with a series of serial injections. One way
that this could be determined would employ the unilateral 6-0HDA lesioned rat model.
HONPs could be implanted into the striatum 3 weeks after the toxin injection. The
animals could be terminated at various intervals (3 wk, 5 wk, 7 wk and 9 wk) after
engraftment. Once the animals were perfused, the immunohistochemistry could be
employed to detect the number and locations of the transplanted cells to accurately track
cell migration and degeneration. This study would provide data showing the cell fate: the
location of the hONPs at a specific time. It is reported that the hESCs will migrate along
the striatal-nigral pathway after transplantation (Burnstein et aI., 2004; Mukhida et aI.,
2008). Therefore, the hypothesis is that the engrafted hONPs may also migrate along
specific pathways. By determining the location at each time point, the migration would
be demonstrated and perhaps hONPs undergo a specific degeneration when they reach a
specific site. Therefore additional cell engraftment at the site of degeneration could be
aimed to overcome this limitation and thereby increase the recovery rate among the
animals.
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In this study, EIA was applied to detect the dopamine levels in animal brains. In the
hONPS engrafted brains the dopamine levels in the behaviorally recovered animals were
higher than in animals without behavioral improvement suggesting that the hONPs were
functional and that the recovery was in part the result of the increased dopamine levels.
Similarly, it has been reported that intracranial transplantation with iPSCS resulted in a
significant improvement of striatal concentrations of dopamine in the behaviorally
recovered MPTP mouse model of PD as measured by high-performance liquid
chromatography (HPLC) (Wolff et aI., 2011). That study used 105 adult human
endometrial derived stem cells (HEDSC) engrafted 5 days after the MPTP lesion in the
mouse model.

The study demonstrated mean DA concentrations were significantly

higher in MPTP lesioned mice after HEDSC compared to MPTP lesioned mice treated
with sham phosphate buffered saline (PBS) transplant. This further supports the
likelihood that the observed behavioral improvement was the result of the increased
dopamine as well as neurotrophin support provided by the engrafted hONPs. To evaluate
this further in a future study, another control group could be included: the dopamine
transporter (DAT) can be blocked by an inhibiter, such as 4-Hydroxy-l-methyl-4-(4methylphenyl)-3-piperidyl 4-Methylphenyl Ketone, or clinically used drugs, such as
benztropine and mazindol (Zahniser et aI., 1999; Wang et aI., 2000). If none of the
animals recover in the following behavioral tests after cell transplantation, it would
support the conclusion that behavioral improvement is directly related to the dopamine
level in animal brains; if some, but fewer animals recover from the Parkinsonian deficits,
it could mean or indicate that the neurotrophic factors produced by the hONPs provide a
microenvironment that can partially protect the dopaminergic neurons from degeneration
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or stimulate an endogenous stem cell formation; and if the same recovery rate is
observed, which is unlikely, it would suggest that the behavioral improvement is not
related to the dopamine levels in striatum. On the other hand, it has been reported that
neurotrophins are crucial in the behavioral recovery of PD models (Singh et aI., 2006).
Therefore it is possible that 6-0HDA lesioned animals could be treated solely with the
trophic factors like BDNF (Sadan et aI., 2009; Ahlskog, 2011), GDNF (Georgievska et
aI., 2002; Azzouz et aI., 2004), or CNTF (von Bohlen und Halbach and Unsicker, 2009)
with some success. In which case, it would also be important to determine the optimized
combination of the trophic factors that could be an efficient supplemental treatment
aiding behavioral recovery in the PD models.

In conclusion, human adult olfactory epithelial-derived neural progenitors have a
great potential as a population for cell-based therapy for Parkinson's disease because of
their capacity to survive, produce dopamine and provide neurotrophic support while
simultaneously not becoming tumorigenic in the toxin-lesioned environment of the
striatum as well as the neurotoxic environment of the Parkinsonian brain. Furthermore,
hONPs have a significant advantage since they can be harvested from the patient's
olfactory epithelium without highly invasive surgical procedures and thus represent an
autologous cell source where the patient is both the donor and the recipient. This benefit
would eliminate the need for waiting lists for histocompatible tissues as well as the use of
immunosuppressive agents typically applied following cell engraftment. Finally these
studies demonstrate that genetic engineering (transfection) is not required for an effective
dopaminergic formation but that the microenvironment of the substantia nigra can
modulate hONPs to become functional, stable, dopamine releasing cells that can offer
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long-term survival following their engraftment without tumor formation. Future studies
are needed to determine if the benefits of hONPs described in this thesis will also apply
in the clinic.
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